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Abstract
GENERATION, ISOLATION AND ASSAY METHODS FOR 
HUMAN LYMPHOCYTE MITOGENIC FACTOR 
by
Thomas Edwin Seay
Activated lymphocytes secrete many products including the 
lymphokine human lymphocyte mitogenlc factor (HLMF). In preliminary 
experiments lymphocytes from peripheral blood and palatine tonsils 
were evaluated as possible sources of HLMF by evaluating their level 
of activation through screening their spontaneous and concanavalln A 
(con A)-induced blastogenlc responses. Tonsil lymphocytes (TL) were 
found to have high spontaneous proliferation as compared to periph­
eral blood lymphocytes (FBL). Cells from both sources responded to 
con A by undergoing a typical blastogenlc response.
Because TL must be obtained septlcally, they are frequently 
cultured in the presence of the antlmycotic agent, Amphotericin B 
(Am B). Since the primary and induced blastogenesls of TL were 
greatly Inhibited by even low concentrations of Am B, those lymphocytes 
were considered unacceptable sources of HLMF, In contrast to TL 
the induced blastogenlc responses of FBL were found to be augmented 
by concentrations of Am B less than 5 yg/ml, but the drug appeared to 
provide no beneficial effect on the quantity of HLMF produced by the 
cells. '
HLMF appeared to be produced optimally in the first 48 hr of 
culture by 10? PBL/ml, cultured in Neuman-Tytell serumless medium 
which had been adjusted to 5 x 10“  ^M 2-mercaptoethanol, and 5-35 Pg 
con A/ml.
Stability of the HLMF activity could best be maintained by im­
mediate dialysis against 0.05 M NH4HCO3 solution, followed by lyophi- 
llzation and storage of the dried material at -80° C until use. 
Activity was retained at -80° C for greater than 3 months. The ac­
tivity was diminished after exposure to 56° C for 30 min, and complete­
ly lost after treatment at 80° C for 10 min or 100° C for 5 min. HIMF 
was insensitive to trypsin and exposure to pH ranges 2-7.
Separation of HLMF and con A blastogenlc activities was accom­
plished by addition of ovalbumin followed by Bio-Gel P-100 column 
chromatography. HLMF activity eluted in the 12,000-20,000 d and
30,000-50,000 d ranges. The lower molecular weight material was ac­
tive in the pH range 3.4-4.6 aa demonstrated by isoelectric focusing. 
The larger molecular weight fractions had a pi of 4.14 1 0.97.
HLMF activated T cells, B cells and unfractionated PBL in assay, 
with the T cell response being generally, but not always greater.
The factor behaved in a dose dependent fashion when assayed against 
unfractionated PBL.
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CHAPTER 1 
INTRODUCTION
Although Che earliest observations of Immunity were recorded by 
Thucydides during an epidemic of the plague in Athens, the ability to 
induce Immunity deliberately as a protective measure was not accom­
plished until the 18th century by the English physician Edward Jenner. 
Since that time there has been active research Into the mechanism and 
regulation of the Immune phenomena.
The existence of soluble, antlgen-speclflc products now known as 
Immunoglobulins was recognized early on, but the mechanisms by which 
the cellular and humoral Immune systems communicated were poorly 
understood. The observation by Lawrence and Rapaport (1) that a per­
manent, specific Immunity could be transferred from one Individual to 
another in a cell- and immunogen-free supernatant from cultured human 
leukocytes led to the concept of Immunoregulatlon by soluble mediators. 
The soluble mediators which act in a hormonal fashion to regulate the 
immune response are referred to as lymphoklnes (2). The study of 
lymphokines Is now a well established parameter of Immunological 
investigation.
The advent of in  v itro  cell culture and activation techniques 
allowed investigators to examine specific components of the Immune 
response in Isolated biological systems. Biological assays usually 
consisted of testing crude or partially purified supernatant fluids 
from mitogen- or antigen-stimulated Immune system cells for the 
ability to Induce the biological activity of interest In a target cell 
population. Target cell populations have included peripheral blood 
lymphocytes (PBL), T-cell and B-cell enriched subpopulations from
2peripheral blood, precursors of T and B lymphocytes, basophils, 
eosinophils, transformed cell lines, macrophages and mast cells.
Observation of a particular phenomenon in a biological assay was 
taken as presumptive evidence for the existence of a soluble mediator 
of the activity; consequently over 90 lymphoklnes are now named for 
their purported biological activity. Unfortunately, lymphoklne bioas­
says may cumulatively measure the similar effects of several factors 
simultaneously. Also a single molecular entity may show varied effects 
that are dependent on the assay system employed. It is, therefore, 
unlikely that 90 different molecular entitles of lymphoklnes exist.
Interpretation of the available information has been Impeded by 
apparent contradictions in the literature, which may have been due, 
in part, to the similarity of data from many different in  v itro systems 
and in the generation, isolation and assay of the various activities. 
Although isolation to homogeneity of some of the lymphoklnes have 
unequivocally established their existence and allowed some physlo- 
chemlcal characterization, that has not been possible for the majority 
of factors due to insufficient quantities of biologically active 
material.
Several authors have attempted to clarify the present mass of 
lymphoklne literature by categorizing the various factors according to 
cellular origin, production conditions, biological activity, isolation 
methods, assay criteria and limited physiochemical data (3-7). Cer­
tainly, a more precise concept of the functional responsibilities of 
a given factor within the confines of the immune response can be 
gained by more carefully defining the generation and assay conditions. 
Investigations into optimum sources, production methods and isolation
3procedures offer prospects for procuring larger quantities of indi­
vidual lymphoklnes. This is necessary to provide sufficient 
homogeneous material to allow specific antibody production and 
physiochemical characterization. It is to these ends that my work has 
examined the generation, isolation, and assay methods of one of the 
lymphoproliferatlve lymphoklnes, human lymphocyte mitogenlc factor 
(HLMF).
A comprehensive review of all parameters of the presently cited 
lymphoklnes is beyond the scope of this dissertation and the reader is 
referred to the several previously mentioned reviews (3-7). This 
literature review will focus on HLMF and the related human lymphopro- 
llferative factors. Finally, a limited review of the mitogen 
concanavalln A is included to familiarize the reader with the physio- 
chemical characteristics as they are presently cited in the literature. 
Because of apparent widespread misconceptions, the mechanism of 
lymphocyte activation by con A Is specifically addressed.
HLMF is so named because of its ability to stimulate directly 
cellular incorporation of radiolabeled thymidine in cultures of autol­
ogous or allogeneic lymphocytes in the absence of all other stimulants 
(7). Several Investigators have described mitogenlc factor assays 
(8-11) which quantitate cellular proliferation by measuring DNA synthe­
sis (12). Generally, replicating cells are exposed to exogeneous 
radiolabeled thymidine for specific periods of time, and the levels of 
incorporated radiolabeled materials are determined by scintillation 
counting. Modifications of culture periods, target cell source and 
assay conditions give substantial versatility in design and applica­
tion to accomodate definition of HLMF's functional responsibilities.
4Several lines of evidence suggest T cells as the source of HLMF. 
Geha and Merler (13) demonstrated HLMF production In agammaglobulinemia 
children who lack B lymphocytes. Rocklin et al. (14) discovered that 
only Immunoglobulin-negative subpopulations of lymphocytes could 
produce HLMF. Geha et al. (15) showed that of the sucrose density 
separated T-and B-cell populations, only the T-cell enriched population 
produced HLMF in response to the purified protein derivative of Tuber­
culin (PPD). Blomgren (16) demonstrated that fractionated T-cells 
produced HLMF after stimulation with mitogens; however, he also 
reported HLMF production by B-enriched subpopulation with Sepharose- 
bound concanavalin A. Relnherz et al. (17) using monoclonal antibodies 
directed against cell surface antigens, separated the T-lymphocyte 
population into 0KT4+ and 0KT4" subsets. They found HLMF to be pro­
duced by antigen-stimulated 0KT4+ , but not 0KT4~ subpopulations.
Other investigators have provided Indirect evidence supporting 
this concept, including loss of HLMF production after depletion of 
certain T-lymphocyte subpopulationB (18), and failure of purified B- 
cells (19, 20) or adherent cells (4) to produce HLMF activity, Larsson 
(21) and Llttman et al. (11), however, demonstrated a macrophage re­
quirement for HLMF production in  v itro . This is in contrast to evidence 
by Insel et al. (22) that suggests HLMF can be generated in the absence 
of macrophages. To date, there have been no reports of endogeneous or 
inducible production of HLMF by an established cell line.
Malnl et al. (23) reported as early as 1969 that lymphocyte acti­
vation was necessary for HLMF production. Various methods of cellular 
activation have been used to Induce HLMF production including mixed 
lymphocytes culture (MLC) (24-30) in which PBL from hlstoincompatible
5donors are co-cultured for up to 120 hours. Some investigators have 
also used a one way MLC with the Intent of reducing the sources of the 
lymphoklnes to a single donor's cells (25-27, 29, 30). De Week et al. 
(30) reported the detection of HLMF activity more often and at greater 
levels using the one-way MLC. Either method results In the occasional 
failure to produce HLMF, which Is probably due to Insufficient foreign 
antigen presentation to either set of lymphocytes.
Many investigators prefer the use of subpopulation specific, 
polyclonal mitogens, such as pokeweed mitogen (PWM) (20, 28, 31), 
phytohemagglutinin (PHA) (20, 31-33) or concanavalin A (con A)
(10, 19, 32-38). These mitogens Induce blastogenesis as well as HLMF 
production in the generating cell cultures, and, therefore, It is 
essential that they be removed or completely Inhibited In any subse­
quent assay for HLMF. Methods have been defined for the removal of 
PHA (39) and con A (40, 41), but some Investigators have reported 
difficulty with complete removal of con A (10). Unlike PWM and PHA, 
con A can be specifically blocked In bloassay without concomitant loss 
of HIMF activity (42).
Additionally, HLMF has been generated from lymphocytes activated 
by specific antigens, other than the previously mentioned histocom­
patibility antigens. PPD (14, 16, 23, 30, 31, 43, 44) and tetanus 
toxoid (TT) (13, 28, 45-48) have been widely used. The use of specific 
antigens, however, necessitates the production of HLMF from antigen- 
sensitive donors, while assay of unpurifled HLMF-contalning superna­
tants requires lymphocytes from antigen-insensitive donors (25).
This requires extensive donor pre-testing and additional Internal assay 
controls.
6HLMF production has also reportedly been Induced by dinitrochloro- 
benzene (DNCB) (13, 46, 48), tumor promoting agents (49), bacterial 
products (27) and extracts (50) with moderate degrees of success.
Some conditions affecting the in  v itro production of HLMF have 
been examined. The lymphoklne Is produced by cells from most lymphoid 
organs, Including peripheral blood, lymph nodes and spleens (51). 
Jacobsson and Blomgren (52) reported, however, that cortical thymocytes 
do not produce any HLMF activity. Several Investigators reported that 
HLMF could not be produced In serum-free media (53, 54). This Is In 
contrast to reports by Duncan (55), Hodge and Inman (unpublished data), 
and others (10, 25) who have demonstrated HLMF activity In supernatants 
generated In various systems in the absence of serum. Cell concentra­
tions varying from 3-10 x 10® cell/ml have been reported as optimum for 
HIMF production (3). Hart et al. (53) reported Increases in yield of 
HIMF after Inclusion of the reducing agent L-cysteine.
Production of HLMF la observed within 6 hours of culture with 
maximum activity being detectable 1-3 days after lymphocyte activation 
(11, 13, 56). Duncan et al. (55) examined the HLMF production timetable 
and reported optimal generation on days 2 and 3 of incubation In serum- 
less medium. This is analogous to the generation kinetics reported for 
HLMF produced by antigen-stimulated mononuclear leukocytes (MNL) In the 
presence of serum (13, 21). The report by Hiramine and Hojo (57) of 
the inhibition of HIMF appearance by puromycin and cyclohexamlde 
suggests that active protein synthesis is required for production 
rather than release of a preformed HLMF by activated cells. This does 
not, however, rule out the possibility that HIMF may be produced as an 
inactive, preformed precursor, which requires cleavage by an Induced
7enzyme for activity (3). The failure of cytosine arabinoBide, vinblastin 
and mitomycin C to block HLMF production suggests that HLMF may be gener­
ated Independently of lymphocyte proliferation (57).
Reports regarding partial characterization of HLMF are difficult 
to compare because of the divergent conditions utilized in the assays 
(58). Initially, Rocklin et al. (14) observed that the 15,000-31,000 
molecular weight fraction of an antigen-produced HLMF supernatant 
chromatographed on Sephadex G-100 Induced antigen-independent prolif­
eration of unfractionated human PBL, Littman and David (11) detected 
mitogenlc activity in the 29,000-56,000 dalton (d) and the 15,000-31,000 
d fractions; however, they qualified the report by stating that B-cell 
mitogenlc activity was detected in significant quantity in all fraction 
pools above 15,000d. De Heck et al. (30) reported HLMF activity in the
40.000-45,000 d range. Rutenberg et al. (47) observed HLMF activity 
from Sephadex G-200 column chromatography of HLMF-actlve supernatants 
only in the post-albumin fraction as was previously reported by Geha 
et al, (13). Amicon ultrafiltration of HLMF-active supernatants 
reported by the same group (47) suggested a molecular weight of
50.000-100,000. HLMF appeared to have a molecular weight of 21,500
on sodium dodecyl sulfate polyacrylamide gel electrophoresis (47). Very 
recently Duncan et al. (55) confirmed the existence of HLMF in the
27.000-35,000 molecular weight range after Blo-Gel P-100 column 
chromatography of 30-fold concentrated HLMF-actlve supernatants.
Limited thermostability and protease sensitivity data suggested 
that HIMF is relatively stable at 56° C, and 1b destroyed by proteolytic 
enzymes but is not affected by RNase, neuraminidase of a-amylase (13,
14, 59). Rutenberg et al. (47) later reported loss of HIMF activity
8after heating at 70° C for 5 min. Sundar et al. noted the loss of 
activity after heat treatment of 100° C for 10 min (49).
The majority of these data were obtained by assaying HLMF active, 
unfractlonated supernatants after various treatments. The results 
from these experiments could have been altered by certain constituents 
of the serum which often were added to the medium prior to supernatant 
generation. Duncan et al. (55) demonstrated, however, that assay of 
unfractlonated supernatants did in fact accurately represent the 
partially purified activity In serum-free systems.
Seravalll et al. (50) reported the Isoelectric point (pi) of HLMF 
to be heterogenous between pH 8 .0-8.5. Recently, this has been contra­
dicted by Hood et al. (60) who reported pis of 7.6-8 .4 for the B cell 
HLMF with molecular weight greater than 26,000. The B cell HLMF 
smaller than 26,000 d was found to have a very broad range of pis from 
4.5-7.5 (60). These Investigators also showed T-cell growth factor (TCGF) 
activity on isoelectric focusing to be restricted to the 6 .5-7.5 pH range.
HLMF appears to exert its effect for at least 48 hours after 
direct contact with the responder cellB (51). Since HLMF can be ab­
sorbed out by an excess of target cells it Is likely that It mediates 
Its effect via a receptor, however, the mechanism by which HLMF 
accelerates DNA synthesis in unstimulated lymphocytes is completely 
unknown (51),
Originally, investigators attributed two types of proliferative 
activities to HLMF; that of (a) direct induction of cellular prolif­
eration and (b) the maintenance of ongoing proliferative action induced 
by prior exposure of target cells to specific antigens or mitogens 
(51). Lately, some investigators have suggested that only the first
9activity is a valid criterion for HLMF Identification, since it has 
been possible to remove the maintenance activity without concomitant 
loss of the direct mitogenlc activity (55).
Literature regarding target cell identification for HIMF has been 
extremely contradictory but progressive. Earlier reports suggested 
that HLMF Induced proliferation in both T and B lymphocytes (13, 14,
19), however, the B lymphocyte response is often (11), but not always 
(32), quantitatively greater than the response of T lymphocytes. HLMF 
has also been reported to stimulate the proliferation of thymocytes 
as well as immunocompetent T lymphocytes (61). Several Investigators 
have suggested that thymocytes ere stimulated to a greater degree than 
lymph node, peripheral blood or peritoneal lymphocytes (62, 63).
These apparent contradictions have been, to some extent, resolved 
with the demonstration of several soluble mediators which potentiate 
ongoing proliferative actions, but fail to Induce direct mitogenesls.
The separation of these activities, which appear to be directed toward 
the T-lymphocyte population (55), has led several investigators to 
suggest that B lymphocytes are the primary target of HLMF (28, 47, 55, 
60, 64).
The consensus is not complete, however, and there are several 
notable exceptions which suggest T-lymphocytes may, in fact, be the 
target (16, 59). Relnherz et al. (17) reported direct proliferative 
Induction by HLMF of all major lymphocyte subclasses (T, B, and Null 
cells), with the proliferative response of the null subclass being 
maximal and significantly greater than either theT-or B-cell fractions.
Certainly, the methods of cell separation used in any of the 
above cited investigations allow cross-contamination among subpopulations.
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The distinct possibility remains that several HLMF entitles may exist, 
and that small variations In production or assay methods may selectively 
enhance for one over the other (58, 65).
Morgan et al. (6 6) observed that proliferation was induced In a 
homogeneous population of non-leukemic lymphoblasts from human leukemic 
blood or bone marrow by the addition of supernatant from mitogen 
stimulated FBL. This led to an active search for the responsible 
factor. Several parameters of lymphoprollferatlon were attributed to 
this factor Including (a) Induction of thymocyte proliferation In the 
presence (60, 67) or absence (6 8) of suboptlnal concentrations of a T- 
cell mitogen, (b) augmentation of proliferation and generation of 
cytotoxic cells by allo-antlgen-stlmulated T-cell populations (6 8 , 69), 
and (c) contribution of a second signal to activated antlgen-speclflc 
helper T cells and maintenance of the cells In long-term culture (70).
In 1978, 61111s et al. (71) further Investigated the production and 
assay parameters and suggested the term T-cell growth factor (TCGF) 
for the responsible lymphoklne. In 1979, investigators at the Second 
International Lymphoklne Workshop adopted a classification system for 
the more thoroughly characterized lymphoklnes (72). Under the system 
the activities previously attributed to TCGF. (71), as well as the 
activities of thymocyte mitogenic factor (6 8), co-stimulator (73), 
killer cell helper factor (6 8), and secondary cytotoxic T cell-inducing 
factor (69) were collectively ascribed to a single molecular entity now 
referred to as Interleukln-2 (IL-2) (72). Presently, the terms IL-2 
and TCGF are used synonomously and Interchangeably In lymphoklne liter­
ature and discussion (74).
The functional criterion for distinguishing HLMF and TCGF Is the
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ability of the former to Induce direct blastogenesls In PBL (7, 55), 
while TCGF cannot (75, 76). TCGF can, however, act as a selective 
mitogen for T cells that have undergone blast transformation as a result 
of exposure to a lectin or antigen (74-76).
Several assays have been described for TCGF which Involve lectin 
or specific antigen-induced peripheral T-cell blasts as targets (9, 
77-81). The presently accepted definitive biological assay for XL-2 
measures the lymphoklne*s ability to maintain the growth of factor- 
dependent cytotoxic T-cell lines (71, 79, 82-84).
The production of TCGF appeared to be T-cell specific in that 
only T-cell lectins (PHA, con A, and PWM) or antigens (alloantlgens, 
tumor antigens) elicited TCGF release from mononuclear cell populations 
(71). Smith et al. (85) reported an adherent cell requirement for 
production. The adherent cell requirement can be substituted by lym­
phocyte activating factor (LAF) (see next section) In mitogen-activated 
systems (8 6). This macrophage product released after mitogen or antigen 
stimulation in turn stimulates T cells to produce TCGF In the presence 
of mitogen or antigen (87). The cellular source of TCGF has now been 
unequivocably confirmed with the discovery of several T-cell lines 
which produce TCGF constitutlvely (8 8 , 89), or after mitogen stimulation 
(90, 91).
As is the case of HLMF, lymphocyte activation 1b required for TCGF 
production (71), but DNA synthesis Is not (69). Many of the methods 
used for HLMF Induction also stimulate TCGF production. There are 
reports of the use of PHA (9, 71, 75-79, 81, 84, 90, 91), con A (55,
71, 80, 90-92) and PWM (71), as activators of TCGF production, Bonnard 
et al, (93) reported con A to be a relatively poor stimulant of IL-2
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production In cultures containing PBL. However, addition of phorbal
myristic acetate (PMA) resulted in approximately a 10-fold Increase In
the amount of IL-2 produced above that produced by con A alone (94).
Alvarez et al. (95) reported optimal production parameters for TCGF to
£
include high cellular concentrations (5 x 10 cells/ml), use of serum- 
free media, and 1% PHA. These Investigators also reported significantly 
less TCGF production when con A was used as the Inducing lectin.
Small amounts of TCGF activity can be detected in con A-stimulated 
cultures within four hours, with maximal activity occurring in the 18-24 
hours Interval and dropping substantially thereafter (96), The peak 
production time of 18-24 hours was confirmed by Alvarez et al. (95) and 
Bonnard et al. (93). The sharp drop in production has been investigated 
by Gullberg et al. (96, 97) who demonstrated that abrogation of TCGF- 
productlon in primary cultures is due to cellular suppression and not 
to lectin-dependent killing of the TCGF-producing T cells.
Physlochemlcal characterization of TCGF has been significantly 
more thorough than for HLMF. The following characteristics have been 
reported by Glllis et al. (98). Molecular weights on AcA 54 and Sepha- 
dex G-100 were 15,000 d, Isoelectric point of the major species was 
6.5, and the activity was maintained after exposure to 6 M urea,
50 mM dithlothreltol, 0.1% sodium dodecyl sulfate (SDS), DNase I,
HNase A, and neuraminidase. Activity persisted in pH ranges from 
2.2-10.0 and after exposure to temperatures of 70° C for 15 minutes. 
Activity was lost after treatment with trypsin, chymotrypsln, sub- 
tillsin, and leucine amino peptidase (98). Duncan et al. (55) reported 
coelution of TCGF and HLMF in the 27,000-35,000 molecular weight 
fractions from Bio-Gel P-100 column chromatography. Most Investigators
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concur with the pratease sensitivity results except for Yung et al. 
(99) who reported TCGF to be relatively Insensitive to trypsin 
treatment at 37° C for 15 minutes. George et al, (100) reported 
trypsin and chymotrypsin sensitivity for TCGF, and noted major peaks 
on Isoelectric focusing at pH 6.8 and 8.0 and a minor peak at pH 7.4. 
They concluded that human IL-2 Is a glycoprotein(s) with heterogeneous 
biochemical properties. • Robb and Smith (101) showed that treatment 
with neuraminidase caused loss of isoelectric point heterogeneity, 
which also suggests protein glycosylatlon.
IL-2 apparently mediates its effects via a specific cell surface 
receptor (102). Time dependent IL-2 absorption studies have been 
performed which show loss of IL-2 activity from supernatants after 
they were incubated at either 37° C or 4° C with antigen- or lectin- 
activated murine spleen and thymus cells (85, 102, 103), lectin- 
activated human FBL (104, 105), and a murine IL-2 dependent, cytotoxic 
T-cell line (106). However, non-activated spleens cells, lipopolysac- 
charide (LPS)-activated spleen cells (85), and a non-T-cell line do 
not absorb IL-2 activity in a time-dependent manner (82). Absorption 
of IL-2 by appropriate target cells is linear with cell number (106), 
and the absorption of IL-2 by CT-6 cells (a murine IL-2-dependent 
cytotoxic T-cell line) is saturable since repetitive incubation with 
three aliquots of a partially purified IL-2 preparation leads to 
diminished IL-2 absorption (106). The absorbed IL-2 activity can be 
eluted from the target cell either by washing laden target cells with 
pH 7.0 glycine buffer (106) or heating laden glutaraldehyde-flxed 
cells to 56° C (102).
Several TCGF dependent cell lines have been reported (71, 79,
82-84), and are of great Importance for definitive assay purposes. The 
target cell of biological Importance, however, appears to be cytotoxic 
and helper T cells which have developed TCGF specific membrane recep­
tor sites secondary to exposure to antigen or lectin (85, 103, 107, 108). 
Freshly Isolated T cells will neither bind nor proliferate in response 
to TCGF, whereas T cells that have had prior exposure to antigen or 
lectin do absorb TCGF and proliferate apparently indefinitely, as long 
as TCGF is present (109). TCGF-responder precursors have been found 
In both Immature, prothymocyte populations, and mature, peripheral, 
thymic-dependent T-cell populations (110, 111),
Although TCGF is well established In unique biological and biochem­
ical parameters, it is not the only immunaprollferative factor described 
that potentiates via an antigen- or lectin-primed mechanism. The 
previously mentioned monokine, lymphocyte activating factor (LAF), was 
first described In 1971 by Gery et al. (112) as an activity produced 
by cultured human peripheral adherent leukocytes that was mltogenlc for 
murine thymocytes but not for PBL. It was also demonstrated to 
augment synerglstically the mltogenlc effects of the lectins con A and 
PHA on murine thymocytes as well as splenic,thymlc-derlved (T) lympho­
cytes (74) and human T cells (113).
Investigators of the Second International Lymphoklne workshop 
classified the LAF under the new title of Interleukin 1 (IL-1) (72).
Under this system, the activities previously attributed to LAF, as well 
as the activities of mltogenlc protein (114), helper peak-1 (115), T 
cell-replacing factor III (116), T cell-replacing factor-mrf (61), B 
cell-activating factor (117), B cell-differentlatlon factor (118), 
were collectively ascribed to a single molecular entity now referred
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to as IL-1. Presently, LAF and IL-1 are used synonomously and Inter­
changeably In the literature and discussion (72, 74).
HLMF and LAF can be distinguished by the ability o£ HLMF to Induce 
direct mitogenesis In PBL (7, 55), while LAF can only augment, but not 
sustain an antigen- or mitogen-induced proliferation (72). Both LAF and 
TCGF appear to augment synerglstlcally antigen- or mltogen-stimulatlon of 
lymphocytes. They can be distinguished, however, on the basis of 
TCGF's ability to promote and maintain in  v itro  long term cultures of 
T cells, while LAF lacks the capacity (72).
There Is, In fact, a functional relationship between LAF and TCGF, 
In that the ability of LAF to augment antigen- or mltogen-stimulatlon 
Is mediated by its preeminent capacity to augment production of IL-2 
(TCGF) (119, 120, 121, 122). In this respect, LAF functions by Inducing 
the synthesis and secretion of the TCGF (94, 120, 121). This link 
between IL-1 and IL-2 Is an essential element In the cell activation 
sequence because it Involves the conversion of a primary macrophage- 
derived maturatlonal signal into a secondary T cell-derived prolifer­
ative signal that results in the amplification of specific Immune 
responses (123).
Assays for LAF (IL-1) utilize mitogen-activated mouse thymocytes 
(124, 125, 126). Briefly, mouse thymocytes are Incubated in medium 
supplemented with 5-102 pooled heat-inactivated serum, 2-mercaptoethanol 
(10~^M), Bubmitogenic concentrations of mitogens (con A or PHA) and LAF- 
active samples for 72 hrs at 37° C in a 5% CO2 Incubator. Tritlated 
thymidine is added after 48 hours and after 24 hours more of Incubation 
the assays are harvested and radioactivity measured. This quantitates 
the ability of LAF samples to augment the suboptimal mitogen effect on
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the thymocytes.
Early Investigations contributed considerable evidence that LAF 
was produced by adherent macrophages and monocytes from peripheral blood, 
spleen, peritoneal and pulmonary alveolar regions (126-128). Calderon et 
al. (129) demonstrated production by peritoneal cells even after treat­
ment with anti-theta antiserum and complement to eliminate T cells. 
Similarly, Hoessll and Waksman (130) showed LAF production by T-depleted 
spleen cells. Confirmation of the cell responsible for LAF synthesis 
was achieved in 1977 by Lachman et al. (131) who showed production by the 
murine macrophage cell line P 388D1. To date, four cell lines have been 
found that produce LAF after stimulation with llpopolysaccharide (LPS), 
also suggesting the need for activation before synthesis (131).
Although LPS is the primary stimulant used for LAF Induction (112, 
114, 126, 127), other B-cell stimulants such as PPD (132), and 
mycobacterial peptldoglycollpids (133) may be used also. Similar to 
the Induction of HLMF and TCGF, con A (55, 112), and PHA (112) induce 
LAF production in PBL cultures. Mlzel et al. (134) found there was LAF 
production after macrophage stimulation with FMA.
The cell line P 388D1 has been a significant source of LAF for 
study. Initially, PMA was used alone to Induce P 388D1 to make LAF.
The levels of IL-1 produced, however, were not high enough to preclude 
an eventual requirement for hundreds of liters of culture fluid to 
obtain a few hundred micrograms of purified IL-1 (123). Mlzel et al. 
(135) modeled a superlnduction protocol after the method used by 
Belllau et e. (136) for Interferon production. Generally,P388D1 cells 
are Incubated for 4 hours with FMA and cyclohexamlde prior to a one-hour 
incubation with actinomycln D. Using this protocol the production of
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IL-1 during the next 24 hour was dramatically Increased relative to the 
IL-1 levels obtained with cells incubated with only PMA for five hours 
(123).
In PBL systems, more LAF was produced In serum-containing, rather 
than In serum-free, medium (51). Although it was reported that human 
mononuclear cell cultures failed to produce LAF In the absence of 
serum (137), others (138) demonstrated LAF production with rat and 
mouse adherent cells in the absence of serum If 2.5 x 10“  ^M mercap- 
toethanol was added to the culture medium. Oppenheim et al. (51) 
reported that LAF production occurred at cell concentrations signif­
icantly less than that required for HLMF production, and they noted a 
decrease In LAF production with increasing cell densities.
LAF activities can be demonstrated In culture supernatantB of 
human leukocytes within six hours of activation, but the maximum level 
of bloactlvity Is not reached until 24-48 hours of culture (126).
Greater production is noted In the human system If the stimulant Is 
continuously exposed to the producing cells, but the cells must be 
left exposed at least 6-8 hours to produce a detectable amount of LAF 
(51).
Human IL-1 Is a 12,000 to 15,000 d polypeptide when obtained from 
human peripheral blood buffy coat mononuclear cells or acute monocytic 
leukemia (AMoL) cells (139). Lachman (140), reported purification to 
homogeneity using hollow fiber flltratlons, ultrafiltration, and 
Isoelectric focusing which resulted In a single peak with a pi of 7.0. 
This is In contrast to the three peaks of activity with pi's of 5.2,
6.0 and 6.9 reported by Oppenheim et al. (74). The charge heterogeneity 
of IL-1 may be due to the same type of posttranslatlonal glycosylatlon
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that has been described for human IL-2 (101), Purification of IL-1 has 
been hampered by Its predisposition to adsorb to proteins, glass 
surfaces, and anion exchangers, all of which significantly reduce 
yield (125).
IL-1 and IL-2 were not resolved by gel filtration, but were distin­
guished by Isoelectric focusing (121). Togawa et al. (125) reported 
LAF activity In two distinct fractions after Bio-Gel P-100 column 
chromatography. These fractions differed also in biological activity. 
The 12,000-22,000 d fraction contained only the predescribed activities 
of LAF; however, the 50,000-70,000 d fraction waB reported to have the 
unique in v itro  functions of induction of human lymphocyte blastogeneais 
and production of a lymphoklne that was chemotactlc for monocytes (141). 
The supernatant from which the two peaks of activity were generated 
contained 5% heat-inactivated human serum. Togawa et al. (125) reported 
the ability to generate the 50,000-70,000 molecular weight form by 
incubation of the 12,000-22,000 dfraction with 2X human serum, suggesting 
that the higher molecular weight form of LAF may actually have been a 
complex of the lower molecular weight LAF and a human serum component(s) 
(125). Lachman (113) recently reported purification to homogeneity of 
IL-1 from cells obtained by therapeutic leukophoresis from a patient 
with acute monocytic leukemia (AMoL). The IL-1 produced by culturing 
AMoL cells in serum-containing medium yielded only a single peak of 
biological activity at approximately 11,000 don sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (113).
The role of IL-1 in T-cell proliferation (112, 141, 142), and the 
generation of helper (58) and cytotoxic T cells (143) is well established. 
Although IL-1 Is an antlgen-nonspeclflc mediator, It functions as an
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essential activating signal In all T-cell dependent, antigen-specific 
Immune responses; the specificity of a given response being defined by 
the eliciting antigen (142, 143). Farrar et al. (119, 144) demon­
strated that IL-1 can be substituted for the macrophage requirement 
in mitogen-actlvatlon of T-cells, however, the stimulatory effects of 
IL-1 are totally dependent upon the presence of macrophages in the 
antigen specific responses (142).
Investigators have suggested that IL-1 may convert Its target 
cells into a primed state during which they develop the capacity to 
bind specific antigen (123). The IL-l-medlated activation step may 
actually involve the induction of the synthesis of cell surface 
receptors for antigen on T-cells (123). Evidence for this theory was 
presented by Puri et al. (145) with the demonstration that IL-1 In­
creased the frequency of T cells binding the synthetic antigen, poly 
[L-Tyr, L-glu-poly (DL-ala)-poly (L-Lys)] (145).
The mechanism by which IL-1 exerts its effects on target T cells
is currently under intensive Investigation by Mlzel et al. (123). It
is clear, however, that expression of IL-1 activity In Immune responses
is dependent on the presence of a second signal, either antigen or 
mitogen, but that IL-1 possesses the ability to modulate the surface 
phenotype of T cells in a manner that Is independent of an antigen or 
mitogen requirement (123). Stadler et al. (146) presented evidence 
that PMA (an in  v itro  analog of IL 1) promotes the progression of T 
cells to a specific part of the phase of the cell cycle and holds 
the cell at this stage. In thiB respect, IL-1 may stimulate quiescent 
T cells to enter a specific early phase of the cell cycle within which 
the cells are not committed to DNA synthesize and division, but rather
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to Initiate the synthesis of specific cell surface components as well 
as lymphoklnes that are essential for the participation of these cells 
In immune responses (123).
In the regard that IL-1 can function as a thymocyte mitogen (112), 
or augmentor of antigen- or raitogen-proliferation (74) via its IL-2- 
productlon enhancement capability (119-122), the behavior Is one of a 
clonal expander after specific challenge (123). The IL-1 activity of 
specific cell surface receptor Induction may be considered one of 
differentiation, In that It causes quiescent T cells to progress to 
the final stage of readiness prior to specific antigen challenge (123). 
Recently, other lymphokines have been reported, whose apparent primary 
function Is essential in the T-cell lineage differentiation.
Ihle et al. (147) reported Isolation and purification to homoge­
neity of a factor which induces 20-a-hydroxysteroid dehydrogenase 
(20-a-SDH) enzyme activity on the cell surface of thymocytes. This 
enzyme reversibly reduces progesterone to 20-a-hydroxypregn-4-en-3-one 
(20-a~OHP), and is strongly associated with maturatlonal sequences 
along the T-cell lineage (148). The existence of this factor Is well 
established in the mouse, but to date, the human equivalent has not 
been observed (147). Since this factor is decidedly different from 
IL-1 and IL-2 In physlochemical and biological parameters, but certainly 
of lymphocyte origin, it Is referred to by Ihle et al. (148) as Inter­
leukin-3 (IL-3),
Recent experiments Indicated that IL-3 may also be involved In 
the regulation of mast cell/basophil growth (147). The appearance In 
IL-3-dependent cell lines after 2-3 months exposure to IL-3 of heavily
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granulated* toluldine blue-positive cell types was suggestive of mast 
cell/basophil presence.
Recently, several groups reported isolation of continuous cell 
lines with basophil/mast cell characteristics whose growth was readily 
supported by partially purified IL-3 preparations (147, 149). Schrader 
et al. (150) demonstrated that persisting (P) cells similarly had the 
characteristics of mast cells. In this case, F cells were generated 
from normal splenic lymphocytes grown In the presence of T-cell growth 
factor preparations after removal of T cells with T lymphocyte 
characteristics.
In addition to the above studies, Yung et al. (99) demonstrated 
that conditioned medium containing IL-3 was capable of supporting the 
long term growth of mast cells, and thus It was named mast cell growth 
factor (MCGF). Proof that IL-3 unequivocably was the responsible 
factor for the mast cell growth in this system remains to be shown, but 
evidence suggests that was the case (147). It Is widely recognized 
that although the Interleukins may be present in lymphocyte culture 
supernatants, there appear to be several other factors Involved in 
lymphocyte activation (151).
Sumner et al. (154) Investigated the ability of some plant lectins 
to specifically agglutinate certain bacteria. These investigators were 
the first to crystallze a lectin from the jack bean (oanaValie 
enB-iformia), which was originally termed concanavalln fraction A.
This fraction of the Jack bean became known as concanavalln A or con A 
and could be used to agglutinate certain bacteria such as Mycobacterium 
and Actinomyces (155).
During the past ten years this globular lectin has been suggested
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to possess numerous Interesting properties (155). Con A forms Insoluble 
complexes with many polysaccharides (156), and glycoproteins (157).
This precipitation reaction of con A has been utilized to assay many 
dextrans, llpopolysaccharIdes and other carbohydrate containing Bub- 
stances (156, 158, 159). Con A Is also a potent mitogen (160, 161,
162) and It stimulates the blast formation of lymphocytes, as well as 
Inhibiting the migration of tumor cells In in  v itro  cultures (163).
Current literature suggests the molecular structure of con A to 
be one of a subunit protein composed of Identical subunits associated 
to form predominantly 55,000 d dimers below pH 6 and tetramers of
110,000 d above pH 7.0 (165). Each subunit contains one manganese ion, 
one calcium Ion, and one saccharide molecule, and the metals are neces- 
sary for saccharide-blndlng activity (166, 167).
Lis et al. (168) reported that con A bound glucose, mannose, glu­
cosamine and other structurally-related residues. Other investigators 
reviewed binding of con A and glycoproteins, as well as methods of 
inhibition and reversal of the binding (169). These have included 
extensive studies on the interaction of normal and pathological serum 
proteins and con A (170) and has been extended to Include Investigations 
of con A-serum protein Interactions of non-human species (171). Lis 
et al. (168) reported the most effective method of con A-glycoproteln 
dissociation to be by addition of the hapten sugar, a-methylmannoside 
(a-mm)•
The usefulness of plant lectins such as con A In the study of the 
control of cell proliferation in lymphocytes was recognized early on 
by Immunologists (172). Studies described the effect of con A on 
target lymphocytes in terms of Increases in membrane fluidity (172),
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glucose consumption (173), membrane protein synthesis (174), biolog­
ical cellular cytotoxicity (175, 176, 177),biological suppression 
(33, 178, 179), and induction of DNA synthesis (180), A major part of 
recent Immunological investigation focused on the molecular and 
biological aspects of the lymphoklnes produced by lymphocytes after 
activation by con A and other mitogenB (10, 19, 32-37, 55, 71, 80, 
90-92, 112). In order to define the functional and biological respon­
sibilities of many of the Induced lymphoklnes (181-184) it was neces­
sary to investigate the mechanism by which con A promoted lymphocyte 
activation and blastogenesls (181), Power et al. (162) described the 
necessity of the mitogen's binding via carbohydrate binding sites to 
the lymphocyte surface as a prerequisite to activation. This was 
later confirmed by Novogrodsky et al. (185) and Dillner et al. (186). 
Internalization of con A does not appear to be required for 
activation (187, 188). 10-20 hours of cell-mitogen contact haB been
reported necessary for irreversible committment to DNA synthesis 
(162, 189). Bloom et al. (190) demonstrated that lymphoklne production 
could occur independent of mitosis; others demonstrated differential 
production of lymphoklnes after con A challenges (181, 191).
Recently, however, it was demonstrated that the production of 
certain lymphoklnes and blastogenesls was, in fact, Inseparable. The 
previously held simplistic version of proliferation of T cells in 
response to con A as a model for the proliferative aspect of the 
Immune responses gave way to a significantly more complex model (192). 
Among the complexities were the interactions between distinguishable 
types of cells and the presence of cell-produced soluble factors 
(Interleukins) (193).
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It is now widely accepted that con A binds to and'activates T 
lymphocytes (71, 186) and macrophages (85, 86, 180). Macrophages 
respond by producing IL-1 (55, 112), which augments the con A-induced 
production of IL-2 (119-122) by a T-cell subpopulation. Con A 
simultaneously activates an IL-2-respondlng population of T lymphocytes 
to develop IL-2 receptors and the cell cycle then stops in this primed 
state (85, 103, 107, 108). Subsequent binding of the IL-2 (generated 
in the same supernatant but by a different subpopulation of T cells) 
results in a characteristic blastogenlc response of the IL-2-reactlve 
primed cells (109, 192-194). This requirement for IL-1 and IL-2 
Involvement in the con A blastogenlc response may serve as a point of 
distinction between con A and the mechanism of HLMF blastogenesls, 
since it appears that the same accessory lymphoklnes are not required 
for HLMF action (55).
The presence of con A in lymphoklne supernatants led to problems 
in distinguishing the direct effects of con A from those mediated by 
other lymphoklnes. Attempts were made to separate con A from the 
various lymphoklne activities by a series of steps Involving ammonium 
sulfate precipitation. Most of the lymphoklne activity was located in 
the 50-702 salt fractions, while con A remained in solution (195). 
Others who used this procedure noted significant con A contamination 
of the resulting lymphoklne-rich ammonium sulfate fractions (36). 
Subsequent gel filtration chromatography using Sephadex G-75 and 
G-100 reduced the amount of contaminating con A, but did not completely 
remove it (36).
Some investigators used a procedure for removal based on the 
affinity interaction of con A with crossed-llnked dextran gels (37).
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In this procedure aliquots of con A generated supernatants were passed 
through columns of Sephadex G-50 or G-100 at appropriate flow rates 
(10, 35, 35). Early reports suggested complete removal of con A was 
possible by this method (34, 35); however, Taylor et al. (10) showed 
there was significant con A contamination even after doubling column 
lengths and reducing con A concentrations applied to the gels (10).
They further demonstrated that protein added prior to cell culture was 
responsible for the failure to remove con A by gel filtration presum­
ably because the added glycoprotein effectively completed with the 
polyglucose gel for glycoprotein binding sites on the con A.
Recently, Duncan et al. (55) showed that con A removal from HLMF 
can be accomplished by Amicon ultrafiltration, followed by Bio-Gel 
P-100 column chromatography. They also confirmed the finding by 
Taylor et al. (10) that con A-actlvity in lymphoklne Bupematants can 
be abrogated in assay by addition of a-methylmannoslde at 0.05 to 0.10 
molar final concentrations (55). This allowed distinction between 
HLMF and contaminating con A activity in untreated or partially 
purified lymphoklne supernatants in that the majority of HLMF activity 
is not abrogated while the con A blastogenlc response is apparently 
completely blocked by the sugar (55).
Certainly, the established interleukins, as well as HLMF, and 
others are unique lymphoklnes which regulate both differentiation and 
proliferation of lymphocyte populations. The exact mechanisms by which 
these factors regulate the well orchestrated Immune response are now 
matters of urgent and active Investigation (151, 152). Understanding 
the products of activated lymphocytes and their mode of action In 
molecular terms is crucial for permitting Immunologists and clinicians
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the use of these regulatory molecules to Intervene selectively In 
altering, amplifying, or suppressing specific components of Immune 
responses (153).
OBJECTIVES
The major problem with obtaining definitive biological and 
physlochemical information on all lymphoklnes is the Inherent diffi­
culty created by the small initial amount of lymphoklne material.
This difficulty is compounded by poorly defined handling and assay 
procedures which result in substantial losses before isolation and 
purification. Initially* it was hoped that alternate sources of 
cells* such as human palatine tonsils* could replace peripheral 
blood and provide larger numbers of starting cultures for super­
natant generation. This, however, was not possible* since tonsillar 
lymphocytes (TL) are activated in  vivot and are continuously producing 
many different lymphoklnes. Secondly* TL are greatly affected by 
antlmycotlc drugs which are necessary to avoid fungal contaminations.
With the resolution of PBL as the source of HLHF and the 
realization that limited quantities of the lymphoklne would be 
available as a starting material, experiments were designed to 
define the optimum generation, handling and assay procedures that 
would result in minimum loss. Ultimately, the desire was to procure 
enough HLMF-active material to purify the lymphoklne to homogeneity. 
This report describes our observations and presents biochemical 
data defining some molecular parameters of HLMF.
CHAPTER 2 
MATERIALS AND METHODS 
Preparation of Peripheral Blood Lymphocytes (PBL), Whole blood 
was obtained In heparinlzed (10 U/ml) syringes by phlebotomy from 
normal adult human donors. The lymphocytes were collected following 
flotation on Ficoll-Paque (Pharmacia Fine Chemicals). They were washed 
twice with Hanks balanced salt solution (HBSS; Microbiological 
Associates), and recovered each time by centrifugation at 400 x g for 
10 min at 20° C or 100 x g for 15 mln at 20° C, as indicated. The 
washed cells were suspended in 10 mis of RPMI-1640 (without glutamine; 
Flow Laboratories) or Neuraan-Tytell Serumless Medium (N-T; Grand 
Island Blologicals Company), supplemented to Blngle strength (IX) with 
penicillin (100 U/ml), streptomycin (100 pg/ml), and HEPES (25 mM;
Grand Island Biological Company) (supplemented medium). Glutamine 
was added to RPMI-1640 to 2 mM but not to N-T medium. Viability was 
determined by trypan blue exclusion (12). The cell concentration was 
adjusted to 1.25 x 10®, 2.5 x 10®, 5 x 10® or 10 x 10** viable cells/ml 
by addition of the appropriate supplemented medium. Cell preparations 
with less than 85Z original viability were not utilized.
Preparation of Tonsillar Lymphocytes (TL). Human palatine tonsils 
were obtained from patients younger than 25 years after routine elective 
surgery for recurrent tonsillitis. The surgery generally was performed 
at least two weeks post-lnfectlon, during which time the patients 
received antibiotic chemotherapy. The excised organs were placed Imme­
diately In Ice cold RPMI-1640 medium, supplemented to triple strength 
(3X) with penicillin (300 U/ml)t streptomycin (300 ug/ml), gentomycin 
(100 pg/ml), amphotericin B (10 pg/ml) (Am B; Grand Island Biological
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Company), and HGPES (25 mM) for transport from the hospital to the labo- 
ratory. Within 2 hours each tonsil was minced in a petri dish contain­
ing 30 ml of (IX) supplemented RPMI-1640, and then the fragments were 
pressed gently through an 80-mesh screen (Cellector; E.C. Apparatus) 
into a petri dish to obtain a single cell suspension. The cell 
suspension was brought to a final volume of 50 ml with supplemented 
RPMI and centrifuged at 20 x g for 2 min to sediment larger debris.
The remaining suspension was layered on Ficoll-Paque and centrifuged 
at 400 x g for 40 min at 20° C, The mononuclear cells were recovered, 
washed twice with HBSS, and recovered each time by centrifugation at 
400 x g for 10 min. The final washed cell pellet was suspended in 40 
ml of supplemented RPMI. Viability was determined by trypan blue 
exclusion, and the concentration was adjusted to 1.25 x 10®, 2.5 x 10®, 
or 5 x 10® viable cell/ml with supplemented (IX) RPMI. Tonsil cell 
preparations with less than 85% original viability were not used.
Primary culture Blastogenesls. PBL or TL Isolated as previously 
described were suspended in supplemented (IX) RPMI-1640 in concentra­
tions of 1.25 x 10®, 2.5 x 10®, and 5.0 x 10® viable cells/ml. PBL 
and TL were each divided into four equal volumes. Am B was added to 
the appropriate stack cell suspension of PBL or TL so that during 
culture in the tissue culture plate, final concentrations respectively 
were 2.5, 5.0, and 10.0 pg/ml. Additional supplemented RPMI was added 
to control (0 pg Am B/ml) and other cultures to bring all cultures to 
the same volume.
Cultures were done in 96-well Falcon micro Test II sterile tissue 
culture plates (Becton-Dlckenson and Co.). Each test well received 
0,2 ml of the cell suspension containing Am B delivered by a 100 pi
30
Hamilton repeating syringe. All wells received 0.025 ml of heat-
inactivated pooled human AB+ serum (HIABS: Flow Labs.). Con A (Miles
Laboratories) was suspended in sterile 1 M NaCl at a concentration of
750-850 pg/ml. This was diluted with supplemented RPMI to 50, 200,
or 250 pg/ml working stock solutions. The concentration of the lectin
was measured with a Beckman Model 35 spectrophotometer (Beckman
Instruments) using - "13.0 (Miles Laboratories). Appro-zou ran, l cm
priate wells were given 0.025 ml of the con A solution which resulted 
in a final concentration in the well of 5, 10, or 15 pg con A/ml.
Hells containing control cells received only supplemented (IX) RPMI.
The final density of cells was 1 x 10®, 2 x 10®, and 4 x 10® per ml.
After 72 hr incubation at 37° C In 95X air-5% CO2 , 0.025 ml of a 
%-thymldlne solution in supplemented RPMI (40 pCi ^H-thymidine/ml;
6 Ci/mM; New England Nuclear) was delivered to each well. The cultures 
were Incubated an additional 18 hr before harvesting. All cultures 
were done in quadruplicate.
Determination of Radioactivity. Cells were harvested on a MASH 
II (Microbiological Associates) sample harvester using 934 AH or GF/C 
glass fiber media strips (Whatman, Inc.). The strips were wet with 
0.16 M NaCl before the cells were harvested.
The cell-laden discs punched from the media strips were placed in 
plastic mlnl-sdnfiliation vials (Kimble) without complete drying. 
Aliquots of 5 ml of Scintlsol (Isolab) were added to each vial and 
radioactivity was determined with a Beckman LS-3155 T liquid scintil­
lation counter (Beckman Instruments). The radioactivity in lectin- 
stimulated cells was determined to IX counting error, and that in 
unstimulated (control) cultures to 5X error. The data are presented
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as meanB of quadruplicate counts on each set of samples with standard
i
deviations. Background counts per minute (cpm) determined with vials
containing Sclntlsol were 25 ± 5. Counting efficiency using %-thymi-
dlne standards (Beckman Instruments) consistently was 62% ± 2%.
Data are presented In the manner most easily Interpreted for the
specific Investigation. Generally, the mean and standard deviation
In quadruplicate samples were determined. From these, the data may be
presented in the following way. The mltogenlc index (MI) or stimulation
Index (SI) may be calculated using the formula:
M.I. or (S.I.) - mean cpm of experimental
mean cpm of control
In some cases, the values are presented as cpm above control. In 
these cases, the value is determined by the following formula:
[Cpm above control ■ cpm experimental - cpm control]
In either case the experimental value (E) represents the cpm of super­
natants or treated material, or partially purified lymphoklne prepara­
tion. The control value (C) may In some cases be the paired reconsti- 
tuted control (R), but generally is either the AB serum control, or
J,
the a-methylmannoBide (ct-mm) paired AB serum control. In each case,
however, the source of every variable Is specified.
Occasionally, It Is most appropriate to use the difference between
the matched, rank-ordered experimental and control values to determine
the mean and standard deviation. The following general protocol Is
used to do this:
Let X, Y, and Z equal representative cpm of either experimental
(E) or control (C) samples. Then rank Xg > YE > ZE and
Xc > Yr > Zr and match X. - X„ - ■ X’
Y? - Y« - ■ Y ’
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and the differences X', Y*, and Z1 are used as single entry units to 
give a mean and standard deviation of differences between experimental 
and control values.
Determination of the Effects of Cell Density. Mercaptan, Mitogen, 
A m _B and Culture Time on HLMF Production. The effects on HLMF produc­
tion of several variables were tested using a microsupernatant genera­
tion method. Generally, PBL were obtained as previously described, 
except that cells were collected from HBSS washes by centrifugation at 
100 x g for 15 min at 20° C, and were resuspended In supplemented H-T 
medium. For the cell density and mercaptan experiments, PBL cell 
suspensions of 12.5 x 10®, 6.25 x 10®, and 3.13 x 10® In the presence 
and absence of 5 x 10”®M 2-mercaptoethanol were made. 0.2 ml of the 
suspension was delivered Into designated wells of a 96-well mlcrotlter 
tray. Test wells received 0.025 ml of a 200 pg/ral con A stock solution 
(final culture concentration was 20 ug/ml) and 0.025 ml additional 
supplemented medium to give a total culture volume of 0.25 ml. Control 
wells received 0.050 ml of supplemented medium. The cultures were 
incubated for 24 hr at 37° C in 953! air-53! CO2 . At the end of this 
period, the microtiter trays were spun at 100 x g for 15 min at 20° C 
In a Beckman TJ-6 Table Top centrifuge equipped with a TH-4 rotor and 
mlcrotlter plate swinging bucket attachment (Beckman Instruments).
100 pi of supernatant were removed In two aspirations of 50 ul each 
with a Finnplpette (Titertek). The 100 pi aliquots of each test super­
natant were placed aseptlcally in corresponding positions In a new 
sterile 96-well mlcrotlter plate and frozen at -10°Cuntil assay. 0.1ml 
of fresh supplemented medium without additional con A was added to the 
cells In each original microsupernatant well with a 100 pi Hamilton
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repeating syringe. The process of removing aliquots was repeated after 
a total of 48 and 72 hr, with each being frozen at -10° C for at least 
24 hr prior to assay.
Optimum con A dose experiments were conducted by adding 0.2 ml of 
£
12.5 x 10 cell/ml solution to designated wells of a 96-well micro- 
titer well. Test wells received 0.025 ml of con A stock solutions of 
50, 100, 150, 200, 250, or 350 ug/ml so that final culture concentra­
tions of 5, 10, 15, 20, 25, and 35 ug/ml were achieved. Test wells 
received an additional 0.025 ml of supplemented medium to reach a 
total culture volume of 0.25 ml. Control wells received 0.050 ml of 
supplemented medium to obtain the 0.25 ml cell culture volume. Samples 
of each test and control well were obtained and stored (as described 
above) at designated time Intervals of 24, 48, and 72 hr. In addition 
to Che test and control wells used for microsupernatant generation, 
identical corresponding tests and controls were set up in matching 
96-well mlcrotlter plates, to evaluate the blastogenlc response over 
time of cells exposed to the same varying concentrations of con A. In 
these experiments, the blastogenlc test and control plates were handled 
exactly as the mlcrasupernatant plates, except that 0.025 ml of % -  
thymidine was added for the last 18 hrs of each test period. At the 
end of the designated 24, 48, and 72 hr test periods, the samples 
were harvested and radioactivity was determined as previously described.
In the Am B experiments, 0.2 ml of the 12.5 x 10® cell/ml 
suspension was added to designated wells of a 96-well mlcrotlter plate. 
Test wells received 0.025 ml of Am B stock solutions of 12.5, 25, 50, 
100, 150, 200, or 250 Mg/ml so that final culture concentrations of 
1.25, 2.5, 5.0, 10.0, 15.0, 20,0, and 25.0 yg/ml were achieved. Add!-
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tionally, each test well received 0.023 ml of a 200 ug/ml con A stock 
solution to give a final concentration of 20.0 ug can A/ml. Control 
wells were brought to a total volume of 0.25 ml by addition of the 
appropriate amount of supplemented medium. 100 pi aliquots of each 
test and control well were harvested as described previously, and 
stored at -10° C for at least 24 hr prior to assay.
In evaluating the effect after 24 hr culture of adding fresh 
mitogen, a different protocol was necessary because of the difficulty 
In removing all the culture fluid from mlcrotlter wells while maintain­
ing sterility and viability. This was accomplished in the following 
manner: PBL were obtained from several donors as described, and were
washed twice In HBSS at 100 x g for 15 min at 20° C. Individual 
donor1s cells were suspended in supplemented N-T at 10 x 10® viable 
cells/ml in tissue culture flasks. Cultures were designed to be 
preincubated (P) In which con A was added to a concentration of 20 
Ug/ml Immediately prior to incubation, or reconstituted (R) In which 
con A was not added until after the 48 hr incubation. After 24 hr 
of Incubation the P culture supernatants were harvested by centrifu­
gation at 400 x g for 10 min, and the cells were resuspended to 10 x 
10® viable cells/ml and the supernatants frozen at -10° C. One half 
of the Individual P cultures received fresh mitogen to a concentra­
tion of 20 ug con A/ml added to the cells, and the other half received 
only supplemented medium and no additional con A, After an additional 
24 hr Incubation under the described conditions, cell culture super­
natants were harvested by centrifugation, as described above and stored 
at -10° C for at least 24 hr before they were assayed.
HLMF Assay. Generally, samples that were to be assayed for HLMF
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Figure 1. Schematic representation of assay of HLMF.
Heparanlzed (10 p/ml) blood; diluted 1:1 HBSS
+
Layer on Flcoll-Paque; 400 x g x 40 min; 20° C
+
Collect PBL (Mononuclear fraction)
+
Wash 2 x HBSS 
, +
Suspend PBS at 4 x 10 viable cells/ml In Supplemented (IX) Neuman-Tytell
+
0.1 ml cell suspension In microtest plate well
+
Add test or control reagents to wells to give concentrations 
as Indicated below. Final volume ■ 0,25 ml/well
,__________________________I__________________
Assay Cultures
A. AB Control:
2 x 10® cells/ml 
10* KIABS
B. Con A Control:
2 x 10® cells/ml 
10% HXABS 
10 ug con A/ml
C. "Test" Wells:
2 x 10® cells/ml 
10% HIABS
0.1 ml of test supernatant
I____________________
q-D-Methylmannoside (ct-mm) paired control cultures 
A. AB Control:
Assay culture + 0.1 M a-mm
B. Con A Control:
Assay culture plus 0.1 M a-mm 
Added before con A
C. Test Wells:
Assay culture plus 0.1 M a-mm 
Added before test supernatant
_ _ _ _ _ _ _ _ _ J
Incubate 37° C, 95Z Air, 5Z CO, x 72 hra
3 +add 1 pCi H-thymidine (6 Cl/mm)/well
+
Incubate 37° C, 95% Air, 5% CO2 x 18 hrs
+
Harvest Cells (MASH II)
Determine Radioactivity
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activity were delivered to the designated wells of a 96-well micro- 
culture tray in 0.1 ml volumes. For the previously described micro- 
supernatant experiments, however, the -10° C frozen samples already 
in trays were thawed and allowed to equilibrate to 37° C for 30 mln. 
Controls were created by placing 0.1 ml of supplemented medium into 
the extra unused wells.
Each test supernatant was assayed in the presence and absence of
0.1M a-mm (Fig. 1). In the assay wells, 0.1 ml of the supernatant
fluid was placed in a microculture well, followed by 0.025 ml of
HIABS. An additional 0.025 ml of supplemented medium was used to
bring the total volume of 0.150 ml. Con A control wells received
0.025 ml of HIABS plus 0.025 ml of a 100 ug con A/ml stock solution.
«!■
AB serum controls received 0.025 ml of HIABS plus 0.025 ml supple­
mented medium. The a-mm paired controls received the same reagents, 
except that 0.025 ml of 1 M a-mm was added instead of the supplemented 
medium.
PBL obtained as previously described were washed twice in HBSS, 
and collected by centrifugation at 100 x g for 15 min at 20° C. They 
were then suspended in supplemented N-T medium at a concentration of 
5 x 10® viable cells/ml. 0.1 ml of the PBL suspension was added to 
every well.
Cultures were Incubated for 72 hr at 37° C in 95% air-5% C02 then 
pulsed with 1 pCl/well of H-thymidlne. After 18 hr more Incubation, 
cells were harvested and radioactivity was determined as described.
HLMF Supernatant Generation. PBL obtained as previously described 
were suspended at a concentration of 10^ viable cellB/ml in supplemented 
N-T medium containing 5 x 10“^ M 2-mercaptoethanol (Fig. 2). Viability,
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as judged by trypan blue exclusion, had to be at least 85% or the 
PBL were discarded.
Usually 5 ml of the suspension were removed and cultured separately 
at 37° C, 95% air-5% CO2 for 48 hr In Corning 25 cm^ tissue culture 
flasks (Coming Glass Works). After the 48 hr Incubation period con A 
was added to a concentration of 20 pg/ml and Incubated for 15 mln at 
room temperature. The supernatant was harvested by centrifugation at 
400 x g for 10 mln at 20° C, and processed or frozen for assay. This 
Is known as the reconstituted (R) supernatant and served as a 
control. The cells collected during centrifugation were discarded.
The remaining cell suspension was cultured at 37° C, 95% air-5%
COg In 75 cm^ tissue culture flanks (Lux Scientific Corporation) for 
24 hr In the presence of 20 ug con A/ml of culture fluid. At 24 hr 
the cells were collected by centrifugation at 400 x g for 10 mln at 
20° C. The supernatant fluid (P-24 supernatant) was processed 
or frozen for assay. The cells were resuspended at a concentration of 
10^ viable cells/ml with supplemented medium. Con A was added to a 
final concentration of 20 ug/ml and the cultures were Incubated for 24 
hr more. The supernatants were then, harvested by centrifugation and 
were processed or frozen as P-48 supernatants. The pelleted cells 
were discarded (Fig 2) .
Processing of Culture Supernatants. Several Methods of volume 
reduction were evaluated, and so was the stability of frozen lymphokine- 
actlve supernatants. 24 and 48 hr mlcrosuperaatants were obtained by 
culturing cells as previously described and they were frozen at -10° C 
without further processing. Cells from the same donors were cultured 
in larger flasks as described In the previous section yielding larger
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Figure 2. Schematic representation of production of HLMF.
Heparanized (10 y/ml) blood 
diluted 1:1 HBSS
Layer on Ficoll-Paque 
400 x g x 40 mln 20° C
Collect
Mononuclear
Cells
I
Suspend Cells at 10 viable cells/ml Wash 2 x HBSS
in culture medium \
Reconstituted "R" culture
1) Incubate 48 hrs 37° C 
95X air, 5X C02
2) Add con A to 20 pg/ml
3) Incubate 15 mln at room temp
4) Centrifuge 
---------------i
Pre-incubated "P" culture
1) Add con A to 20 pg/ml
2) Incubate 24 hrs 37° C, 
95% air, 5X C02
3) Centrifuge
V 
Cells
(discard) Supernatant
1
Cells P-24
Supernatant
1) Suspend @ 10^ cells/ml
2) Add con A to 20 pg/ml
3) Incubate 24 hrs 37° C,
95X air, 5X C02
4) Centrifuge
+
Cells
--^
P-48
(discard) Supernatant
*RPMI-1640 requires 10% HIABS for optimum HLMF production; 
there appears to be no requirement for serum in Neuman-Tytell 
serumlesB medium.
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volumes of 24 and 48 hr supernatants. All supernatants except those 
stored for stability studies were assayed the same number of days after 
harvest. All supernatants were assayed at approximately one-half the 
original concentration and in the presence of 0.1 M a-mm.
Supernatants raised in culture flasks were divided into several 
portions, each of which was processed in a different way and assayed 
for HLMF activity. One portion was stored at -80° C for 1 week, with 
aliquots set aside for assay at 6 weeks, 3 months, 6 months. Another 
portion was concentrated 30-fold by dlaflltration using a DiaFlo 
YM-10 Ultrafiltration membrane (Amicon Corporation) under 40 psi N2 
pressure and stored at -80° C. A third portion was lyophllized 
without prior dialysis and stored in powder form at -80° C. A fourth 
portion was dlalyzed against 0,05 M NH4HCO3 solution, pH 7.3, for 24 
hr, lyophllized and stored at -80° C.
On the day prior to assay, the lyophllized samples from each 
protocol were rehydrated to their original volume, and dlalyzed 
against supplemented N-T medium for 24 hr in preparation for assay.
On the following day, the dlalyzed samples were filter-sterilized 
with a 0.22 pm filter (Gelman Science), and assayed according to the 
standard mltogenic factor assay. Mlcrosupernatants were thawed, 
equilibrated and assayed according to the described assays for micro­
supernatants against target cells from the same donor. Assays were 
begun on the seventh day after the original cultures were harvested.
Sephadex G-100 Affinity Chromatography. In the optical density 
experiments, a known amount of con A contained in 8-10 mis of RPMI was 
loaded by gravity flow onto a (1,5 x 30 cm) 30 ml Sephadex G-100 
column equilibrated with PBS, pH 7.2. After 30 min incubation at room
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temperature without flow, elution commenced and one Vt (30 ml) was
collected. The 0D2qq was measured. Initial concentration and eluate
IT
concentrations were determined by 0D2QQ* EjJiO ^ cm ■ 13.0.
For the ^H-con A trace experiments, con A concentrations of 
10-20 Mg/ml were trace labeled with ^H-con A (34.5 Ci/mm; New England 
Nuclear). After the trace labeled con A stock solution cpm were 
determined, a known amount was loaded on the column, Incubated and 
eluted as above. Radioactivity was determined in a Beckman LS 3155 T 
Liquid Scintillation counter.
In the bioassay for con A experiments, an 8 ml sample of a stock 
solution of con A at 4 or 10 Mg/ml was loaded on G-100 columns. The 
eluate was concentrated to 1/2 the volume of the original stock 
solution and assayed according to the standard mitogenlc factor assay, 
except that the processed eluates were used as test supernatants.
To determine the effect of serum on removal of con A from RPMI- 
1640, a bioassay evaluation was also used. Nine ml of RPMI-1640 
containing 20 Mg con A/ml and 10% serum were loaded by gravity flow 
onto a (1.5 x 30 cm) 30 ml Sephadex G-100 column. Incubation, elution, 
and bloassay were as previously described, except that a 20 Mg con A/ml 
control was included and the assay was accomplished in the presence 
and absence of a-mm.
Molecular Sieve - Affinity Chromatography with Sephadex G-100. 
Concentrated HIMF-active supernatants were fractionated using a (1.5 
x 92 cm) 145 ml column of Sephadex G-100 (Pharmacia Fine Chemical).
The gel matrix was equilibrated with PBL, pH 7.2. Ascending chromatog­
raphy was accomplished at room temperature using gravity flow at a rate 
of 12-15 ml/hr with a pressure head of 50 cm ^0. The column was
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equipped with an Interchangeable 0.22 pm ln-llne filter (Gelman 
Sciences), and 3-ml fractions were collected using an ISCO 
(Instrumentation Specialties Co.) model 328 fraction collector. The 
column was calibrated with the following molecular weight standards: 
bovine serum albumin (mol wt 67,000), ovalbumin (mol wt 43,000), 
chymotrypBinogen A (mol wt 23,000), and rlbonuclease A (mol wt 13,000). 
Ferritin (1 pg/ml: mol wt 440,000) was used to determine the exclusion 
volume. A single two ml sample of 30-fold concentrated supernatant 
or control supernatant, which consisted of 130 pg con A/ml In PBS, 
pH 7.2 In the presence and absence of 0,1 H glucose, aa well as 150 pg 
con A/ml In 30X N-T medium were fractionated and bloassays performed 
according to the HLMF assay.
Since the Sephadex 6-100 also acted as an affinity column for con 
A, It was necessary to strip the bound con A by eluting It with one 
column volume of 0*1 M a-mm In PBS, pH 7.2. This was followed by re­
equilibration of the column with two volumes of PBS, pH 7.2 prior to 
each supernatant fractionation.
Afflgel-Ovalbumln Affinity Chromatography. Two ml of 20 pg/ml con A 
stock solution, or MF-actlve supernatant were loaded onto columns (0.7 x 
20 cm) comprising 8 ml Af f lgel-ovalbumin equilibrated with PBS, pH 7.2, 
(Bio-Rad Laboratories). The exclusion volume of these column was three ml. 
Loading was accomplished by gravity flow at a rate of 1 ml/15 mln.
After loading, the columns were Incubated at room temperature for 30 
mln without flow. The subsequent elution with one column volume of 
PBS was done at a rate of 1 ml/15 mln. Samples were concentrated and 
assayed biologically as described In the previous section.
Bio-Gel P-100 Column Chromatography. A (2.6 x 100 cm) 375 ml
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column of Bio-Gel P-100, equilibrated with PBS, pH 7.2 was used for 
molecular sizing and fractionation. Ascending chromatography was 
accomplished at 4° C using gravity flow at a rate of 12-15 ml/hr and 
a pressure head of 75 cm H20, The column was equipped with an inter­
changeable 0.22 pm in-line filter (Gelman Sciences), and three ml 
fractions were collected with an ISCO Model 328 fraction collector.
The column was calibrated with the following molecular weight 
standards: bovine serum albumin (mol wt 67,000), ovalbumin (mol wt 
43,000), chymotrypsinogen A (mol wt 23,000) and Ribonuclease A (mol 
wt 13,700). Ferritin (1 pg/ml, mol wt 440,000) was used to determine 
the exclusion volume. Three-five ml samples of con A at known con­
centrations, or 30-fold concentrated P supernatants were fractionated, 
and the OD2gg read on a Beckman Model 35 spectrophotometer.
Isoelectric Focusing. Preparative isoelectric focusing in flat 
beds was accomplished using Fharmalytes 3-10 (LKB) with Ultradex (LKB) 
serving as the support medium in the plate.
Supernatant culture fluids demonstrating HLMF activity in bloassay 
were concentrated by lyophlllzatlon after dialysis for 24 hr against 
HH4HCO3 solution (0.05 M; pH 7.3) at 4°C. They were rehydrated to l/30th 
the neat volume with PBS, pH 7.2. Con A was removed from some 
samples by Afflgel affinity chromatography. Other samples were 
fractionated by Bio-Gel P-100 column chromatography and the HLMF- 
actlve fractions pooled. Samples from each column were again dlalyzed 
against NK4HCO3 for 24 hr at 4° C, lyophllized and rehydrated with PBS, 
pH 7.2 to l/30th the original supernatant volume.
Plates three mm in depth with Ultradex were prepared and allowed 
to dry to the evaporation limit at room temperature. A 2.0 cm x 9.5
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cm section of the gel was removed and mixed with the rehydrated sample. 
The gel-sample slurry was repoured into the section and the plate was 
allowed to equilibrate for 30 mln at room temperature. The gels were 
then focused at 10° C using an LKB multlphor apparatus (LKB, Biochem). 
Electrophoresis was at 8 watts constant power until no further drop 
in mllllamperage could be detected.
The gel was sliced into 15 equal sections and each was placed 
in a plastic funnel. The gel slices were eluted with 3-5 ml of 
degassed, deionized water. The pH of the eluates was determined 
with the use of a standard reference electrode and Brinkman Model 103 
pH meter (Brinkman Instruments). The eluates were then dlalyzed 
against 10 volumes of PBS, pH 7.2 to remove Fharmalytes, and then 
against 10 volumes of supplemented N-T medium in preparation for assay. 
Samples were then assayed using the pre-descrlbed Btandard HLMF assay.
pH Stability. Biologically active, NH^HCO^-dlalyzed supernatants 
were dlalyzed at room temperature against sodium barbitol and sodium 
acetate-HCl buffers (196) which were adjusted to pH values of 2.0, 3.0, 
5.0, and 7.0. When the pH inside the control dialysis bag equilibrated 
to the designated buffer pH, timing was begun. After 30 mln at the 
designated pH, samples were removed and placed into supplemented N-T 
medium which had been adjusted to pH 7.0, at 4° C. Control samples 
were dlalyzed against the supplemented N-T only but at appropriate 
temperatures. All samples were dlalyzed overnight in the cold against 
fresh supplemented N-T medium in preparation for bioassay. All 
samples were assayed for HLMF activity according to the described 
procedure.
Thermostability: HLMF-active supernatants were tested for thermal
ustability at 56° C for 30 mln, 80° C for 10 mln, and 100? C for 5 mln. 
Aliquots of two ml of unconcentrated supernatants were placed In 1-ml 
pyrex test tubes with stoppers. Each sample was placed In a water 
bath set at the appropriate temperature. Timing was begun after the 
sample had reached the test temperature. The sampleB were Immediately 
cooled to 10° C in an Ice bath, removed, dlalyzed against supplemented 
N-T medium and assayed for HLMF activity.
Trypsin Sensitivity. Immobilized trypsin (1238 U/gm; Millipore 
Corporation) was washed repeatedly in several volumes of 0.1 M Trls- 
HCl solution, pH 8.0. HLMF-actlve supernatants that had previously 
been dlalyzed against large volumes of NH4KCO2 , pH 7.2 were dlalyzed 
against the 0.1 M Tris-HCl buffer. A small aliquot of each dlalyzed 
supernatant was reserved to serve as a control. Two-ml fractions 
were treated with 10 pg of the washed enzyme for 1 hr at room 
temperature. The reaction was terminated by the addition of 10 pi 
of dilsopropylfluorophosphate (DIFP) (0.54 M), Each sample was then 
centrifuged at 100 x g for 30 mln to remove the Immobilized trypsin 
and the treated supernatants were dlalyzed against PBS, pH 7.2 to re­
move unreacted DIFP. Dialysis against supplemented N-T medium was 
performed in preparation for bloassay.
Optimum Bioassay Parameters. PBL obtained as previously described 
were suspended In supplemented RPMI-1640 medium at densities of 
4 x 10®, 2 x 10®, and 1 x 10® viable cells/ml. Cells were stimulated 
with concentrations of 5, 10, and 15 Pg con A/ml, in the presence of 
10Z HIABS.
In the experiments designed to test the media and serum support 
capabilities cells at 2 x 1 0  ^viable cells/ml were suspended In
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supplemented RPMI-1640 or supplemented N-T. Cells were stimulated 
with 10 pg con A/ml In the presence of 2.5, 5.0, or 10Z HIABS.
Finally, cells at 2 x 10® viable cells/ml were suspended In 
supplemented N-T and stimulated with 10 ug con A/ml In the presence 
of 10Z HIABS or heat-lnactlvated serum autologous to donor cells.
After 72 hr Incubation at 37° C In 95Z air-5% COg, 0.025 ml of a 
40 pCl thymidine/ml solution In the appropriate medium was deliv­
ered to each well. The cultures were Incubated 18 hr more.
Cells at a density of 2 x 10® viable cells/ml In supplemented 
RPMI-1640 fortified to 10Z with HIABS and stimulated with con A as 
described above were harvested on a MASH II sample harvester equipped 
with 934-AH, GF/A, GF/C, or GF/F glass fiber media strips (Whatman, 
Inc.) (Table 1). Radioactivity was determined as previously 
described.
Log transformation of the filter media raw data was performed 
according to Dei et al. (197). A two way analysis of variance (ANOVA) 
was performed on the log transformed data to evaluate sources of 
variation. Multiple comparisons were made by construction of 
Bonferronl 95Z confidence Intervals about means and difference between 
meanB to evaluate performance of the filter media. The confidence 
limits were constructed using Dunnett’s Q* (198) statistic and the 
standard error of the difference used to establish the limits was 
computed from the error mean square of a one-way ANOVA. When 
Individual comparisons were made between experimental control values, 
Dunnett's test was used (PL. 05).
HLMF Dose Response. Biologically active fractions from Bio-Gel 
F-10 0 column chromatography were pooled according to peaks of activity.
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TABLE 1
CHARACTERISTICS OF WHATMAN GLASS MICROFIBER FILTER MEDIA®
Grade
Weight
(g/m2)
Thickness
(mm)
Particle size 
retention (li)
Flow rate 
(ml/sec)
934-AH 0.30
GF/A 52 0.25 1.5 13.0
GF/C 55 0.26 1.2 10.5
GF/F 75 0.44 0.7 6.0
®Taken from Whatman Inc., 1975 and 1979.
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Samples were dlalyzed against NH^HCO^ (0.05 M; pH 7.2), lyophllized, 
and rehydrated with distilled water to l/30th the original supernatant 
volume. In preparation for bloassay, samples were dlalyzed against 
supplemented N-T. Serial dilutions were made in supplemented N-T 
medium and were assayed for HLMF biological activity as described.
Biological assays for human TCGF were performed concomitantly 
according to the protocol of Warren et al. (9). Briefly human PBL 
were obtained as described and were Incubated for 5 days at 37° C,
95% air-5X CO2 at a density of 1 x 10^ viable cells/ml In supplemented 
N-T medium made 10% In heat-lnactlvated fetal calf serum (HIFCS:
Grand Island Biological Company) and containing con A at a concentra­
tion of 20 pg/ml. At the end of five days, the cellB were washed 
X 3 with supplemented N-T medium, and resuspended at 2 x 10^ viable 
cells/ml.
Serial dilutions of the 30-fold concentrated supernatants were 
made and assayed for their ability to sustain the proliferative 
activity of the con A-actlvated PBL. Control supernatants of TCGF- 
rlch material were obtained commercially from Bethesda Research 
Laboratories.
Assays were Incubated for 48 hr at 37° C, 95% air-5% CO2 and 
3
pulse labeled with H-thymldlne. Radioactivity was determined as 
described for other bioassays after 18 hr more incubation.
Subpopulatlon Target Identification. PBL were separated into 
T-cell enriched or B-cell enriched populations. The T-cell enriched 
population was obtained using the nylon wool separation method of 
Julius et al. (199) except that HBSS waB used instead of Eagles 
minimum essential medium. For each experiment, 3.5 pg pieces of
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nylon wool (Leukopak Laboratories), were washed In 0,2 N HC1, rinsed, 
and dried at 100° C In a drying oven. Then each 3.5 g sample was 
packed into a 60 cc sterile syringe and autoclaved for 20 mln at 
15 pounds pressure. Before use, the syringe was filled with N-T 
containing 10% HIFCS. After incubation of the packed column for 25 
mln at 37° C, 2 i 10® cells in 3 ml N-T containing 10% HIFCS were 
added. After a 30 mln Incubation at 37° C, the non-adherent cells 
were eluted by addition to the wool of 150 ml of HBSS containing 10% 
HIFCS, The cells which did not adhere were termed the T-lyraphocyte- 
enrlched population. E-rosette testing, with 10% sheep red blood 
cells (SRBC) (96) for T-lymphocyte markers showed 83% rosettlng cells 
and viability of the eluted cell population was 90% as determined by 
trypan blue exclusion.
B-enrlched cell populations were obtained by a combination of 
SRBC E-rosetting, and Flcoll-Paque density gradient centrifugation 
as described by Jencks et al. (200). PBL at a density of 4 x 10® 
cell/ml were mixed 1:1 with freshly washed SRBC at a concentration 
of 0.5% (0.05 cc packed cells In 10 ml medium) and Incubated at37°
C for 15 mln in a heated water bath. The mixture was then layered on 
Flcoll-Paque and centrifuged In a TJ-6 table top centrifuge for 10 mln 
at 200 x g at 20° C. The remaining mononuclear layer was collected 
and the procedure repeated. After the second E-rosette, Flcoll- 
Paque centrifugation, floating MNL cells were collected, washed twice, 
and examined for T-lymphocyte markers and viability. The floating MNL 
layer of cells were termed B-cell enriched population. The cells had 
<1% E-rosettlng cells and were >95% viable.
The standard HLMF assay was performed on whole HLMF-active super-
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natants, pooled active Sephadex G-100 chromatography fractions and the 
pooled active Bio-Gel P-100 chromatography fractions using unfractio- 
ated PBL, T-enriched, or B-enrlched cells from the same donor as target 
cells. The cell density In each case was adjusted to 2 x 10® viable 
cell/ml In the wells for assay.
CHAPTER 3 
RESULTS
Primary Blastogenlc Responses of Peripheral Blood Lymphocytes.
The responses of PBL to con A are shown In Figure 3. Three different 
concentrations of cells were utilized In the experiments. The con­
centration of con A ranged from 0-15 pg/ml. In the absence of con A 
the PBL were not very active. The magnitude of the Incorporation of 
%-thymidine was, of course, greater as the concentration of the cells 
Increased. When cultured with con A, the cells assimilated much more 
of the JH-thymldine. The maximum response of stimulated cells became 
smaller as cell concentration Increased. Peak responses were achieved 
at 10 pg con A/ml and 1 x 10® FBL/ml.
The range of modifications of the PBL response to 10 pg con A/ml 
Induced by Am B is illustrated In Figure 4. The Incorporation of 
^H-thymidine by unstimulated cells was not affected by Am B (Table 2). 
The drug had a profound effect on the responses of the cells to the 
optimal dose of con A, however. Although the proliferative response 
to con A usually was enhanced when the concentration of Am B was 2.5 
or 5.0 pg/ml (Table 3), there were a few cases of negligible effect or 
even suppression noted at these intermediate doses (Fig 4). At these
q
concentrations of the drug, up to 66% greater Incorporation of H- 
thymldlne was noted when compared to the Incorporation Induced by con 
A in the absence of Am B (Table 3). When Am B was present at 10 pg/ml, 
however, there was a significant decrease (up to 65% in the data 
reported; Table 3) in the proliferative response when compared to the 
responses at 0, 2.5, or 5 pg Am B/ml.
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Figure 3. The incorporation of ^H-thymidine by PBL 
stimulated with 0, 5.0, 10.0, or 15.0 pg con A/ml culture fluid. 
Single representative experiment selected from a group of ten;
SD > ± 10Z mean. •, 106 PBL/ral; I, 2 x 106 PBL/ml; i, 4 x 106 
PBL/ml.
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Figure 4. The effect of various concentrations of Am B 
(0, 2,5, 5.0, or 10.0 Mg/ml) on the incorporation of 
^H-thymidine by PBL (2 x 10^/ml) activated with 10 pg con A/ml 
culture fluid. Three representative experiments selected from 
a group of ten. S.D. £ ± 10X mean. •, Exp, 1; ■, Exp. 2,
A, Exp. 3.
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TABLE 2
Am B Modification of Spontaneous Proliferation 
of Peripheral Blood Lymphocytes
^Spontaneous Proliferation In presence
proliferation of Am B at indicated ug/wl
(cpm) (cpm)
Experiment means ± S.D.; n ■ 4 2.5 5.0 10.0
1 543 ± 85 489 + 35 400 + 28 363 ± 74
2 255 ± 44 285 ± 49 263 ± 31 189 ± 19
3 307 ± 12 293 ± 44 300 ± 49 317 + 67
4 325 ± 36 383 ± 72 299 ± 51 245 ± 31
*PBL at 2 x 10® viable cells/ml.
54
TABLE 3
Am B Modification of Con A-lnduced proliferation of
*
Peripheral Blood Lymphocytes
*Sponteneous X Change In con A-lnduced
proliferation +Con A-induced proliferation In presence
(cpm) proliferation of Am B at Indicated pg/ml
Experiment means ± S.D.; n**4 (cpm) 2.5 5.0 10.0
1 543 ± 85 120,532 ± 8,933 50 33
±
-28
2 255 ± 44 62,409 ± 7,614 24 25 -65
3 307 ± 12 127,706 ± 18,505 16 26 -41
4 325 ± 36 119,990 ± 5,569 66 45 -35
*PBL at 2 x 10® viable cellB/ml.
+Con A at 10 pg/ml.
■^Negative sign Indicates that the cpm were less than con A control.
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TABLE 4
Am B Modification of Spontaneous Proliferation 
Response of Tonsillar Lymphocytes
% Change spontaneous
*
Spontaneous proliferation in presence
proliferation (cpm) of Am B at indicated pg/ml
Experiment means ± S.D.; n*4 2.5 5.0 10.0
1 27,563 ± 2,961 -61+ -80 -95
2 15,217 ± 2,482 -58 -89 -98
3 31,682 ± 1,711 -88 -98 -99
4 6,650 ± 961 -21 -64 -98
*TL at 2 x 10® viable cells/ml.
^Negative sign indicates that the cpm were less than control.
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Primary Blastogenlc Responses of Tonsil Lymphocytes. Tonsil cells 
cultured In the absence of con A and Am B Invariably exhibited signlf- 
leant Incorporation of H-thymidine (Table 4) as compared to FBL 
(Table 3). The magnitude of Incorporated radioactivity ranged from a 
few thousand cpm to tens of thousands. It always was greater than 
that expressed by unstlmulated PBL (Fig 3) at a similar cell concen­
tration (2 x 10®/ml). Am B at all concentrations teBted significantly 
reduced this Incorporation (Table 4, Fig5A). When the concentration 
of the drug was 10 pg/ml, the Incorporation of radioactivity was 
reduced by 95%-99%, and the radioactivity was at the level of that 
seen In unstlmulated PBL at the same cell concentration.
When tonsil cells were stimulated with con A In the absence of 
Am B, the stimulation Indices (SI) ranged from 5 to 9. This was much 
less than the stimulation Indices one often noted for PBL similarly 
treated. The latter indices ranged from about 50 to 500. The low 
indices of tonsil cells reflected the high background radioactivity, 
however, and were the result of the formula for calculating SI. If, 
for example, the indices were calculated using the radioactivity of 
control cells cultured with 10 pg Am B/ml, they would fall In the 
range of the indices noted for PBL. The magnitude of the radioactiv­
ity in the stimulated TL was sb great or greater than that character­
istic of stimulated PBL.
Am B markedly reduced the proliferative responses of tonsil cells
stimulated with 10 ug con A/ml (Fig 5 B) , All levels of the drug
significantly and progressively reduced the Incorporation of 
3H-thymidine, At the highest concentration of the drug, the Incor­
poration of radioactivity was diminished about 72% to 97% (Table 5).
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Figure 5. The effect of various concentrations of Am B 
(0, 2.5, 5.0, or 10 pg/ml) (a) on the spontaneous Incorporation 
of ^H-thymidine by TL, and (b) on the Incorporation induced 
by the presence of 10 ug con A/ml culture fluid. The TL were 
at 2 x 10^/ml. Three representative experiments selected from 
a group of six; S.D. £ 1 10% mean, s, Exp. 1; ■, Exp. 2;
A, Exp. 3.
CPM X 10-3
01 oo o
fO
<R
>3 pi 
n o
fca
I nw  •
01
o
o
150
2.5 
5.0 
7.5 
10.0 
A
m
B
(ug/m
l)
CPM X 10“3
ra
o —. m «  a.o  o  o  o  o
58
TABLE 5
Am B Modification of Con A-lnduced Proliferation 
of Tonsillar Lymphocytes
% Change in con A-lnduced
Con A-induced proliferation in presence
proliferation (cpm) of Am B at indicated pg/ml
Experiment means ± S.D.; n*4 2.5 5.0 10.0
1 212,290 ± 12,729 -33+ -50 -72
2 98,505 ± 10,536 -19 -33 -87
3 176,737 ± 9,539 -21 -54 -88
A 60,952 ± 6,911 -34 -75 -97
*Con A at 10 pg/ml; TLat 2 x 10® viable cells/ml.
+Negative sign indicates that the cpm were lesB than con A control.
59
Effect of Con A on Amphotericin B-Inhlblted TonBil Cells. Although 
Am B reduced the incorporation of thymidine, there was still some 
incorporation, the amount of which varied depending on the source of 
the TL. It was of interest to examine the response to con A of the 
drug-suppressed population of TL. In these experiments the density of 
the cells was 1, 2, or 4 x 10^/ml. The cells were cultured in the 
presence of 5 or 10 Mg Am B/mlt and their responses to various concen-
3
trations of con A were measured by cellular incorporation of H- 
thymidlne.
At a drug concentration of 5 ug/ml, the shape of the dose curves 
(Fig 6) resembled those of PBL stimulated in the absence of the drug 
(Fig 3). In the absence of con A, the incorporation of radioactivity 
at cell densities of 1-2 x 1 0^/ml was very low, and at a density of
/ n
4 x 10 cells/ml JH-thymidine wsb taken up much less than one would 
have expected by uninhibited spontaneous proliferation (Table 4).
Am B evidently suppressed proliferation as waB shown earlier (Table 4). 
The optimal dose of con A in the presence of 5 Mg Am B/ml was 5-10 
Mg/ml (Fig 6). Unlike the response of FBL (Fig 3), the maximum incor­
poration of radioactivity occurred with the higher densities of cells 
(Fig 6).
When TL were cultured in 10 Mg Am B/ml, spontaneous proliferation 
was essentially ablated, even at the highest cell density (Fig 7). In 
spite of the presence of the drug, however, con A Induced incorporation 
of H-thymidine, The shape of the dose curve (Fig 7) resembled that 
for the response of TL (Fig 6) in the presence of 5 Mg Am B/ml. At 
the lowest cell density (10^/ml), uptake of radioactivity was about 
one log unit lower than it was at double (2 x 1 0® cells/ml) that cell
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Figure 6 . The effect of Am B (5 pg/ral) on the response of 
TL to con A at 0, 5.0, 10.0 or 15 pg mttogen/ml culture. The 
response was measured by the cellular Incorporation of
3
H-thymidine. Single representative experiment selected from 
a group of three; S.D. < ± 103! mean. •, 10® TL/ml;
■ , 2 x ID6 TL/ml; 1, 4 x 106 TL/ml.
AO
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Figure 7. The effect of Am B (10 pg/ml) on the response of 
TL to con A at 0, 5*0, 10.0 or 15 pg con A/ml culture fluid. The 
response was measured by the cellular Incorporation of thymidine. 
Single representative experiment selected from a group of three; 
S.D. < ± 10% mean. •, 106 TL/ml; ■, 2 x 106 TL/ml; 1, 4 x 106 
TL/ml.
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density. Incorporation of H-thymidine at each dose of con A was 
greater with increasing cell density.
The Effect of Cell Density and Mercaptan on Production of HLMF.
The effects of the density of the lymphocytes cultured in serumless 
medium on production of HLMF was studied. The density of the 
lymphocytes was 2.5 x 10®, 5 x 10®, or 10 x 10® per ml in the wells 
of tissue culture plates, and the concentration of con A waa 20 pg/ml. 
There was no detectable production of the lymphokine at the lowest 
density of cells (Fig 8), and the greatest lymphokine activity occurred 
in microsupernatants raised at the highest cell density. Microsuper­
natant HLMF activity in several experiments tended to decrease after 
24 hr culture. Samples for assay were removed after 24, 48, and 72 
hr. The wells were replenished with an equal volume of fresh medium 
after the 24 and 48 hr samples of microsupernatant were taken, but 
additional con A was not presented to the cells.
Mercaptoethanol boosted the lymphokine activity about 50% after 
24 hr of culture at cell densities of 5-10 x 10® per ml. It had no 
significant effect on HLMF activity in microsupernatants taken at 48 
or 72 hr although it was present In the appropriate replenishment 
medium. After the first 24 hr, there was a decrease in lymphokine 
activity which occurred even in the absence of the mercaptan (Fig 8).
The Concentration of Con_A Optimal for Production of Mltogenlc 
Factor. PBL were cultured in Neuman-Tytell medium with mercaptoethanol 
for 24 hr In the presence of 5-35 tig con A/ml (Fig 9). The micro- 
aupematants were recovered and assayed in the presence of a-mm for 
HIMF activity. The volume withdrawn was replaced with an equal volume 
of medium containing mercaptoethanol but no con A. After an additional
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Figure 6 . Effect of cell density and mercaptan on 
production of HLMF. Cell densities are as indicated in the 
absence (-) or presence (+) of 5 x 10“® M, 2-oercaptoethanol, 
o, 10 x 10® cells/ml; (-). •, 10 x 10** cells/ml; (+).
□, 5 x 10® cells/ml; (-). i, 5 x 10® cells/ml; (+).
A, 2.5 x 10® cells/ml; (-). A, 2.5 x 10® cells/ml; (+),
n
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Figure 9. Effect on HLMF production by 10 x 10® 
cells/ml In response to varying concentrations of con A. 
o, 5 yg/ml; • „ 10 pg/tnl; □, 15 ug/ml; ■, 20 tig/ral; 
A, 25 yg/ml; A, 35 pg/ml.
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24 hr another sample was taken, and the medium was replenished as 
described. Finally, a third sample was taken after a total of 72 hr 
culture. When the stimulating dose of con A was 5 or 10 yg/ml, HLMF 
activity was recovered in the 24 hr mlcrosupematants, but the factor 
apparently was no longer produced by the cultures stimulated with those 
doses of the lectin (Fig 9). HLMF was produced not only during the 
first 24 hr by cultures stimulated with 15, 20, 25, or 35 yg con A/ml, 
but production apparently continued during the next two 24-hr sampling 
periods. There was greater mitogenlc activity In the 48 and 72 hr 
mlcrosupematants than there was In the 24 hr mlcrosupematants when 
the dose of con A was 20, 25, or 35 (Jg/ml,
A comparison of producer cell population proliferation with HLMF 
production as a function of dose of con A was made. During the first 
24 hr only the cultures given 5 yg con A/ml signaled proliferation by 
incorporating a little ^H-thymdllne. HLMF activity in the microsuper­
natants was maximal when the dose of con A was 10 ug/ml although 
there was no proliferation during that time at that dose (Fig 10).
HIMF was produced at all doses of con A regardless of whether there 
was proliferation In the producing cell population. After 48 or 72 
hr culture in the presence of con A, the dose responsible for peak 
proliferation remained at 5 Pg con A/ml, but the extent of incorpora- 
tlon of H-thymidine Increased greatly with Increasing time of culture 
(Fig 11 and 12). Further, proliferation at higher doses of con A 
began to be apparent and that phenomenon progressed with time. The 
HLMF activity was greatest In the mlcrosupematants corresponding to 
the cells showing the least proliferation after 48 or 72 hrs culture.
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Figure 10. Temporal relationship of proliferation and 
HLMF production with varying doses of con A during the lBt 
24 hr period of incubation. HLMF production; 
a, proliferation.
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Figure 11. Temporal relationship of proliferation to 
HLMF production vlth varying doses of con A during the 24-48 
hr period of incubation. ■» HLMF production; a, proliferation.
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Figure 12. Temporal relationship of proliferation to 
HLMF production with varying doses of con A during the 
48-72 hr period of incubation. A , HLMF production;
A , proliferation.
I70-
J  6 0
a
0
150-
tL
«” 40-
o
0.
o
20-
1-----
r3.0
O
T3
“i----- i----- i-----i----- r1
15 20 25 30 35
Con A (ug/ml)
69
The Effect of Amphotericin _B (Am B) on HLMF Production. Various 
doses of Am B were given to microcultures of PBL stimulated with con A. 
The supernatants were assayed for HLMF activity. In 4 out of 7 experi­
ments, each examining the effect of several doses on Amphotericin B on
different donors' PBL, HLMF activity in the supernatants waB progres­
sively depressed with increasing doses (Fig 13). In the other
experiments, however, there was no effect by the drug on production of
this lymphokine.
The Effect of Fresh Mitogen on HLMF Production. The cells from 
several donors were cultured. One half of the cultures received fresh 
mitogen after 24 hr culture, while the remainder received only sup­
plemented medium. After harvesting the culture supernatants, they 
were assayed for HLMF activity. All the P-24 hr supernatants Induced 
similar levels of blastogenesis in target cells and contained signif­
icant levels of HLMF as evidenced by the number of a-mm-reslstant 
counts. Mitogenlc indices In all cases were greater than 3.0 (Table 
6).
In the cultures which did not receive additional con A after 24 
hr, there was a significant drop in both the test and a-mm-paired 
controls. The MI of the 48 hr cultures were significantly less than 
for the corresponding 24 hr cultures.
For the cultures which received fresh mitogen there was only a 
slight decrease in the 48 hr test supernatants relative to the 24 hr 
cultures. The a-mm control demonstrated, however, there was an 
equivalent or greater amount of HLMF produced during the 48 hr culture 
if fresh mitogen was added. There appeared to be no endogenous HLMF 
produced in the R cultures in any case.
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Figure 13, Representative experiments showing the two 
general effects of Am B on HLMF production, o, Exp. 1;
•, Exp. 2.
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TABLE 6
HLMF Generation In Presence and 
Absence of Additional Mitogen
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Source Test
a-mm 
Paired Control Mla
AB Control 1,162 656
Con A Control 36,468 693
Donor 1 P 24 hr' 76,709 3,699 3.4
(no Con A) P 48 hr 12,005 1,309 1.2
R° 74,692 1,096 -
Donor 2 P 24 hr 110,275 3,593 4.9
(no Con A) P 48 hr 16,072 1,937 2.6
R 127,104 738 -
Donor 3 P 24 hr 109,455 5,629 6.5
(+ Con A) P 48 hr 89,759 5,013 5.7
R 118,846 868 -
Donor 4 P 24 hr 112,112 2,559 3.2
(+ Con A) P 48 hr 94,068 4,183 5.3
R 93,294 793 -
aH1 m a-mm paired P 
a-tnm paired R
I*
P * Preincubated culture supernatant; con A was added at culture 
Initiation.
°R « Reconstituted culture supernatant; con A was added 15 mln 
before culture termination
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Effects of Processing of Culture Supernatants on Expression of 
HLMF. Large volumes of culture supernatants are required to obtain 
even small quantities of lymphokines. Reduction of supernatant vol­
umes to convenient levels usually is necessary. There also are long 
periods of time during which supernatants must be stored while 
samples are undergoing aBsay. Therefore, It la necessary that super­
natants be processed (concentrated or stored) with minimal loss of 
activity. Several handling procedures were investigated to determine 
which were most advantageous toward preserving IIIMF activity.
Microsupernatants were obtained from cells cultured In microtiter 
trays for 24 hr, and they were stored at -10° C without further proces­
sing. The residual cells were replenished with medium and con A, and 
the microsupernatants were recovered after an additional 24 hr and 
were stored frozen. Cells from the same donors were cultured also 
in flasks. This permitted larger volumes to be obtained compared to 
those taken from microcultures. SupernatantB were recovered after 
24 hr, and the cells were replenished with medium and con A. After 
another 24 hr the supernatants were harvested. When appropriate, 
these large volumes were reduced prior to storage. Ultimately all 
supernatants except those stored frozen for six weeks or three monthB 
were assayed the same number of days after harvest. All supernatants 
were assayed at one-half the neat concentration and in the presence 
of 0.1 M ct-mm.
Supernatants raised In microcultures and stored frozen activated 
target FBL (Table 7). The supernatants were neither dlalyzed nor 
concentrated prior to assay. The most active usually were those 
harvested after 48 hr culture.
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TABLE 7
Effect of Various Treatments of Supernatants
on the Activity of HLMF
Microculture Freeze
Supernatant -80°
Sample (cpm) (cpm)
Cell Control 745 + 76a 626 + 102a
Cell Control & a-mm 579 ± 99 360 + 143
Con A Control 79,890 ± 8,104h 61,838 ± 4,001'
924 2,189 + 910° 648 ± 1 57 o
948 2,356 ± 246 603 + 122
1024 2,309 + 940 644 ± 511
1048 1,649 ± 833 147 ± 42
1124 1,579 ± 239 315 ± 197
1148 2,480 ± 652 281 ± 52
1224 1,496 ± 647 314 ± 10
1248 2,396 ± 696 730 ± 105
R-24 - 975 ± 226
R-28 ** 777 ± 269
amean ± standard deviation; (n “ 4).
^Radioactivity (cpm) was corrected for that of the cell control. 
^Radioactivity (cpm) was corrected for that of the corresponding 
R control and a-mm for this and all following cpm in this column.
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TABLE 7 (cont)
Effect of Various Treatments of Supernatants
on the Activity of HLMF
Freeze 6 wk Freeze 3 mo
-80° -80° 
Sample (cpm) (cpm)
Cell Control 278 + l i 1 536 ± 318a
Cell Control & a-mm 302 + 30 424 + 28
Con A Control 99,728 ± ll,156b X* ID * o o + 7,783&
924 2,448 ± 579° 1,158 ± 536°
946 2,666 ± 1,096 2,963 ± 272
1024 2,152 ± 810 1,587 ± 592
1048 1,531 ± 109 2,108 ± 1,125
1124 1,438 ± 363 1,715 ± 401
1148 876 ± 702 2,151 ± 300
1224 1,202 ± 252 1,553 ± 682
1248 1,140 + 98 1,076 ± 517
R-24 802 + 152 1,224 ± 105
R-28 1,615 ± 536 460 ± 69
amean ± standard deviation; (n " 4).
^Radioactivity (cpm) was corrected for that of the cell control. 
^Radioactivity (cpm) was corrected for that of the corresponding 
R control and a-mm for this and all following cpm in this column.
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TABLE 7 (cont)
Effect of Various Treatments of Supernatants
on the Activity of HLMF
Ultrafilter Lyophllize Dlalyze, lyoph-
freeze -80° freeze -80° ilize, freeze -80°
Sample (cpm) (cpm) (cpm)
Cell Control 600 1 53 a 719 ± 118a 998 ± 232 a
Cell Control & a-mm 501 + 74 386 ± 24 486 ± 62
Con A Control 55,698 ± 3,525* 55,032 1 4,655* 83,523 ± 10,176
924 0(3 582 ± 415° 2,442 ± 618°
948 980 ± 337 602 ± 117 2,969 ± 216
1024 532 ± 152 539 ± 406 3,318 ± 208
1048 830 ± 275 216 + 75 3,319 ± 691
1124 0 201 ± 91 2,556 + 192
1148 491 ± 78 592 ± 176 1,422 + 486
1224 429 ± 201 805 ± 116 2,855 ± 1,230
1248 459 ± 59 273 ± 84 675 ± 231
R-24 922 ± 286 835 ± 257 910 ± 57
R-28 666 ± 132 727 ± 235 891 ± 189
amean ± standard deviation; (n ■ 4).
Radioactivity (cpm) was corrected for that of the cell control.
°Radioactivity (cpm) was corrected for that of the corresponding
R control and a-mm for this and all following cpm in this column.
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The supernatants raised In culture flasks were divided into 
several portions, each of which was processed in a different way and 
then assayed forHLMF activity. One portion was frozen to -80° C for 
one week. Upon subsequent analysis, the KLMF activity was low in all 
samples except number 1124 and ranged from 0-30% of what one expected 
based on the activity in the microculture supernatants (Table 6).
After storage at -80° C for six weeks or three months, however, the 
activity was recovered to the level found in the microcultures in 
75% of the samples (Table 6).
Some supernatants were concentrated 30-fold by dlaflltratlon and 
then frozen to -80° C. When assayed, HtlfF activity waB not detected 
in supernatants 924 and 1124, and the activity in the other samples 
was only 19-50% of that in the corresponding microculture supernatants 
(Table 6).
Another portion was lyophillzed without prior dialysis and the 
powder was stored at -80° C. When these samples were rehydrated to 
one-tenth their original volumes, precipitation occurred. This 
evidently was a salting-out effect. After removing the precipitates 
by centrifugation, the supernatants were assayed. The HUIF activity 
again was less than expected, and ranged from 11-54% of that expected.
Others supernatants were dlalyzed In NH^HCO^ solution before 
lyophilization. These samples were rehydrated to one-tenth their 
original volume with medium and precipitation did not occur. Additional 
medium was then added to bring the samples to their original volumes. 
They were dlalyzed in supplemented medium and assayed. Only the activ­
ity in sample 1248 was less than that of the corresponding mlcro- 
cultures. The activities In the other samples ranged from the same
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to 30% greater than those of the corresponding microculture super­
natants, and were as good or better than those In supernatants 
stored at -80° C for six weeks of three months.
Sephadex Affinity Chromatography, Sephadex G-100 was tested for 
Its ability to remove con A from RPMI-1640 medium. In optical density 
and trace label experiments (Table 8), con A was removed with 97% 
effectiveness as measured by O&280 nm or scintillation counting. In 
the bioassay experiments, the eluate was assayed for its ability to 
Induce primary blastogenesls In target lymphocytes. In these 
experiments, a 4 pg or 10 pg con A/ml stock suspension showed no 
significant change over the AB control experiment which indicated 
complete removal of the lectin.
However, when serum was Included to 10% (v/y) In the con A 
suspension applied to the column, the bloassay results of the eluates 
showed minimal removal of con A and, In fact, the eluateB stimulated 
greater Incorporation of %-thymldlne than did a con A control of 10 
pg con A/ml.
Molecular Sieve-Affinlty Chromatography with Sephadex G-100. 
Control experiments with con A In PBS proved the ability of Sephadex 
G-100 to remove all the contaminating con A (Table 9). The Inclusion 
of 0.1 M glucose had no apparent effect on the binding of con A to 
the Sephadex, even though glucose Is a known competitive inhibitor 
of the con A-Sephadex Interaction. When the con A at 150 ug/ml in 
30 X-N-T medium was fractionated, significant con A contamination was 
noted near the column volume (Fractions 43-46) corresponding to the 
less than 7000 weight range. Fractionation of con A-containing, HLMF- 
active 30 X P supernatants showed unbound con A to be in similar
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TABLE 8
Concanavalin A Removal by Sephadex 
G-100 Affinity Chromatography
Exp Load (mg) Elute (mg) X Removal
Optical Denslty2 80 nm
1 29.07 1.20 96
2 33.85 0.87 97
3 25.64 0.78 97
3H - Con A (cpm)
1 48,825 1,460 97
2 86,300 2,524 97
Bioassay, thymidine Uptake (cpm; absence of serum)
Test X Removal
AB Control 1,351
Con A Control 110,151
4 yg Stock (Sephadex Eluate) 1,079 99
10 yg Stock (Sephadex Eluate) 1,602 99
3
Bloassay, H-thymldlne Uptake (cpm; In presence of serum)
Test a-mm X Removal
AB Control 1,193 792
Con A Control 50,370 1,515
Exp. 1 137,397 2,247 0
Exp. 2 146,205 2,167 0
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TABLE 9
Molecular Selve-Affinity Chromatography 
with Sephadex G-100
X Unbound Con A Activity
Corres­
ponding Con A/ Con A + Con A + Con A in
a-mm Resistant 
activity in
Fraction Mol wt PBS Glu NT MF Sup MF Sup
19 vo 0 0 3.0a 0 0
22 0 0 1.9 1.1 0
25 63,400 0 0 2.5 0,9 0
28 12,200 0 0 1.4 1.5 0
31 28,200 0 0 1.5 1.1 0
34 19,000 0 0 3.4 2,2 58.5
37 13,300 0 0 24.4 23.8 36.4
40 0 0 20.5 30.3 5.1
43 0 0 21.0 27.3 0
46 vT 0 0 20.4 11.7 0
a.
CPM fraction - CPM AB Control
-,19 J * «v * 100 ~ * unbound con A activity
£ fa (CPM fraction - CPM AB Control)
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TABLE 10
Bio-Gel P-100 Column Chromatography
of Con A from Sephadex Affinity Chromatography
Molecular Z Total by
Weight Category
V0-45K 51%
45K-35K 47%
35K-25K 2%
25K-15K 0%
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positions (Fractions 43-46).
The majority of HLMF activity was noted, however, in fractions 
(34-40) which eluted just prior to the con A contaminated fractions, 
and there was significant overlap between the activities.
To evaluate the molecular weight characteristics of the eluting 
con A, fractions exhibiting con A activity were pooled and rechroma­
tographed over Bio-Gel P-100 (Table 10). The results showed greater 
than 513! of the contaminating con A was in excess of 45,000 in molecular 
weight, and 983! was greater than 35,000.
Afflgel-Ovalbumln Affinity Chromatography. Con A appeared to be 
removed from HLKF-active supernatants in substantial quantities by 
binding to the ligand ovalbumin. Afflgel-ovalbumin was tested also for 
its ability to remove con A from either HLHF-actlve supernatants 
generated in Neuman-Tytell medium, or from a 20 pg con A/ml stock, 
suspension. In both cases, substantial amounts of contaminating con A 
were removed, but because of product expense and variability of 
effective binding between lots, this was not considered the most 
favorable alternative (Table 11).
Bio-Gel P-100 Column Chromatography. Molecular sieve chromatog­
raphy was used to investigate the apparent molecular weight of con A 
and the mltogenlc activity in the supernatants. The elution profile 
of con A from several suppliers is shown in Figure 14. All three 
samples were tested in PBS, pH 7.2, or in supplemented medium. Each 
sample eluted in the molecular weight range of 35,000-60,000 with a 
major peak of activity at 45,000. There were, however, significant 
amounts of biologically active con A in all fractions between 15,000 
and 60,000,
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TABLE 11 
Removal of Con A by
Afflgel-Ovalbumln Affinity Chromatography
Sample Test a-mm Resistant
AB 1,193 792
Con A (10 pg/ml) 50,370 1,515
MF Supernatant 60,634 4,000
Adsorbed Supernatant 4,435 2,720
Adsorbed con A 1,472 1,447
83
Figure 14. Elution profile of commercially 
obtained concanavalin A from Bio-Gel P-100.
•» Pharmacia; ■, Miles Laboratories; A, Sigma.
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Figure 15. Elution profile of the biological activity 
of a 30-X P supernatant fractionated on Bio-Gel P-100. 
Proliferation of target cells in the absence (A) and 
presence (B) of 0.1 M a-mm.
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When 30-fold concentrated F supernatants were fractionated on 
Bio-Gel P-100 the elution profile was a broad area of biological 
activity ranging between 20,000 d and the exclusion volume (Fig 15A). 
There were, however, two peaks of a-mm-reslstant activity (Fig 15B). 
The smaller 30,000-45,000 d peak waB observed In fractions where con 
A activity was found to be decreasing progressively. The larger
50,000-65,000 d peak corresponded to fractions showing the greatest 
amount of con A activity In test samples. Essentially no optical 
activity was observed In the eluted samples, a-mm caused at least 
partial ablation of counts with all samples tested.
Since con A Is found In significant quantities as a contaminant 
in the expected site ranges of HLMF activity, a method was devised 
increase the apparent molecular weight of the lectin and thereby facili­
tating itB separation from HLMF by molecular sieving. Ovalbumin, the same 
glycoproteln-blndlng moiety as on the afflgel matrix, was added to P 
supernatants to a final concentration of 33 pg/ml. After dialysis 
and concentration to 1/30 the original volume, the active supernatant 
was chromatographed. The elution profile of biological activity in 
the absence of the competitive inhibitor a-mm was a single band of 
activity which peaked at greater than 65,000 d (Fig 16A). Two peaks 
of light absorption were noted. The smaller peak was at the exclusion 
volume and the larger peak corresponded to the free ovalbumin position. 
Although the molecular weight of ovalbumin Is 43,000, It consistently 
eluted In the 50,000-60,000 range on Bio-Gel P-100.
Three district peaks of a-mm resistant activity were observed.
The lower molecular weight peak was observed In the 12,000-20,000 
range. The Intermediate peak was between 30,000 d and 50,000 d and
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Figure 16. Elution profile of the biological 
activity of a 30-X P supernatant containing 1 mg/ml ovalbumin 
fractionated on Bio-Gel P-100. Proliferation of target 
cells in the absence (A) and presence (B) of 0.1 H a-mm.
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corresponded to a similar peak observed previously (Fig 15). The 
larger molecular weight peak again corresponded positionally to the 
primary peak of blastogenlc activity attributed to con A in the assay 
of fractions derived from supernatants which had no ovalbumin added 
prior to chromatography.
In the >65,000 d peak, significant reduction of con A counts 
was noted when assayed with a-mm. However, in fraction 9 of the 
Intermediate peak, and fractions 14-18 of the lower molecular weight 
band, the a-mm moderately boosted cpm by 250-1400 cpm above those 
observed in the absence of the inhibitor.
Isoelectric Focusing of HLMF-Active Supernatant Fluid. Concen­
trated HLMF-active supernatants from which some con A was removed by 
Afflgel affinity chromatography showed two broad areas of activity 
(Fig 17). The larger area"encompassed a pH range of 5.3-8.2 with the 
peak occurring at pH 6.7. The smaller area spanned pH 3.5 to 4.5 
with the peak occurring at pH 4.2.
When concentrated HLMF-active supernatants were fractionated 
over Bio-Gel P-100, at least two distinct peaks of activity were 
observed. The smaller 12,000-20,000 d and intermediate 30,000 to 
50,000 d activities were focused separately and presented different 
profiles. The lower molecular weight material showed three minor 
areas of activity, the largest of which was a broad band between 
pH 3.4 and 4.6 (Fig 18). Minor peaks of activity were noted at pH 
5.2, 5.7, 8.7, and 9.5.
The larger molecular weight fraction showed two distinct peaks 
of activity (Fig 19). The larger peak was broad, ranging from pH 
3.25 to 5.11 with a defined peak at pH 4.14. A lesser peak of activity
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Figure 17. Concentrated HLMF Active 30-X F supernatant 
fluid from Affigel-ovalbumin affinity column was focused in a pH 
gradient of 3.5-10 and assayed for HIMF activity. The pH 
of each fraction was measured and plotted (o). HLMF 
activity in each fraction is illustrated by the bars.
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Figure 18. HLMF Active 12,000-20*000 molecular weight 
fractions from Bio-Gel P-100 molecular sieve chromatography 
of 30 X P supernatants containing 1 mg/ml ovalbumin were 
pooled and reconcentrated. The concentrated material was 
focused In a pH gradient of 3.5-10 and assayed for HLMF 
activity. The pH of each fraction was measured and the 
gradient plotted (o). HLMF activity In each fraction Is 
Illustrated by the bars.
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Figure 19. HIHF-active 30,000-50,000 molecular 
weight from Bio-Gel F-100 molecular sieve chromatography 
of 30 X P supernatants containing 1 mg/ml ovalbumin 
were pooled and reconcentrated. The concentrated material 
was focused in a pH gradient of 3.5-10 and assayed for 
HU1F activity. The pH of each fraction was measured and 
the gradient plotted (o). HLMF activity in each fraction 
is illustrated by the bars.
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was observed In the pH range 8.07-8.5
pH Stability of HLMF-Active Supernatants. HIMF-active super­
natants were tested for their stability within the pH range 2-7.
All supernatants tested showed at least 83% activity remaining after 
all treatments (Table 12). Three of the five supernatants tested were 
significantly enhanced by exposure to the pH 7 buffer, and one of 
these was persistently augmented after all pH exposures.
Thermal Stability of HIMF-Actlve Supernatant. HLMF-active 
supernatants were tested for thermal stability at 56° C, 80° C, 
and 100° C. The results are shown in Table 13. The HLMF-actlvlty 
was partially lost in two of three experiments at 56° C for 30 min.
At 80° C for 10 min, all three supernatants retained between 21Z 
and 45% of the control activity. Treatment at 100° C for 5 min 
completely irradicated the activity. Ho precipitation was noted 
in any of the experiments, after any treatment.
Trypsin Sensitivity of HLMF-Active Supernatants. HLMF-active 
supernatants were tested for their sensitivity to immobilized trypsin 
(Table 14). Five of the ten supernatants showed essentially no loss 
of activity after a one hour exposure to trypsin at room temperature. 
The remaining five supernatants had activities of 58, 65, 71, 75, and 
82%. The data suggested that HIMF activity was resistant to trypsin 
digestion.
Optimum Bioassay Parameters. Cells at varying densities were 
assayed for optimum blastogenlc response to concentrations of con A 
ranging from 5-15 pg (Fig. 20). In the absence of stimulation, the
3
highest concentration of cells gave the highest H-thymidine incorpo­
ration. At the lowest concentration of. con A tested, however, the
TABLE 12
pH Stability of HWF-Act±ve Supernatants
Supernatant
Number
Control*2
MI
pH-7^
HI
X Control0 
MI
pH-5
MI
X Control 
MI
pH-3
MI
X Control 
MI
pH-2
MI
X Control 
MI
1 2.12 2.46 116 2.00 94 1.80 85 1.79 84
2 1.95 2.37 121 2.10 107 2.05 105 2.48 127
3 2.96 3.37 114 2.52 85 3.04 102 2.99 100
4 2.58 2.32 90 2.38 92 2.39 93 2.35 91
5 2.30 2.08 90 2.37 103 2.33 101 1.91 83
Control HI
^Test MI -
cTest MI 
Control MI
a-ram resistant supernatant cpra
a-mmresistant AB control cpm 
a-mm resistant supernatant cpm after trypsin exposure
Control material vas maintained at pH 7.2 In 
supplemented N-T continuously until assay.
X 100
a-mm resist AB control cnm 
X control MI
\o
to
TABLE 13
Thermal Stability of HLKF-Active Supernatant
Supernatant X Activity^
Number HI3 Untreated 56° C x 30 min 80° C x 10 min 100° C x 5 min
1 1.95 100 96 21 0
2 2.96 100 40 36 0
3 2.30 100 20 45 0
Supernatant ct-mm-r esis tan t cpm 
AB control a-mm-resistant cpm
t, Treated Supernatant a-mm-resistant cpm - AB control a-mm-resistant cpm
X activity = ----------------------------------------------------------------------
Untreated Supernatant a-mm-resistant cpm - AB control a-mm-resistant cpm
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TABLE 14
Trypsin Sensitivity of HLMF-Active Supernatant
Supernatant
Number Control Ml? Test Ml?
X of 
Control MI?
1 2.38 2.23 94
2 3.68 3.58 97
3 1.55 1.75 100
4 4.24 3.01 71
5 2.87 1.87 65
6 1.74 2.75 100
7 2.29 1.88 82
8 3.26 1.90 58
9 2.27 2.39 100
10 2.53 1.86 74
aControl MI ■ a-mm-reslstant supernatant cpm______
a-mm-resistant AB control cpm
^Test MI - a-mm-reslstant supernatant cpm after trypsin exposure
a-ram-resistant AB content cpm
°Test MI „ „  _ „ .
Control MI X 100 " % C ontr o 1 MI
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order reversed and the lowest density of cells Incorporated the most 
thymidine. Although this remained true at the higher dose, there 
was no statistical difference in the number of cpm of the 1 x 1 0  ^
and 2 x 10® densities Incorporation of ^H-thymidine by cells at the 
highest density was significantly lower than the incorporation at 
intermediate or lower densities at all concentrations of con A.
The Intermediate density of cells was selected for use in the 
experiments designed to determine optimum serum concentrations.
Three concentrations of HIABS were tested for their ability to support 
cell growth in the presence of varying concentrations of con A in two 
media (Fig 21). Supplemented RPMI-1640 proved to be a significantly 
inferior to supplemented N-T in its cell support capability at all 
serum concentrations tested. At the lowest con A concentration tested,
3
the higher concentration of serum resulted in the lowest level of H- 
thymidine incorporation. At the Intermediate concentration of con A
3
there was no appreciable difference in the H-thymidlne incorporation at 
any of the serum concentrations in the supplemented RFMI, and these 
values were not generally higher than for the other dose of con A.
For cells suspended in the supplemented N-T, the number of cpm 
at the intermediate dose of con A was significantly less for the 10% 
HIABS than for the lower concentration tested. At 15 pg con A/ml, 
there was an appreciable drop in the ability of 2.5Z serum to support
3
H-thymldlne incorporation in both media, and in both media, the effect 
of 5.0Z and 2.5% HIABS were statistically indistinguishable.
When media containing HIABS or heat inactivated serum autologous 
to donor cells were tested for their relative support of incorporation 
of thymidine by the PBL, no appreciable differences were noted at
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Figure 20. The incorporation of H-thymidine by PBL 
stimulated with 0, 5.0, 10.0, or 15.0 pg con A/ml culture 
fluid. Single representative experiment selected from a 
group of ten; S.D. <±10% mean. •, 10® PBL/ml;
■ , 2 x 106 PBL/ral; A, 4 x 106 PBL/ml.
5 10
Con A (ug/ml)
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Figure 21. The proliferative response of 2 x 10 PBL/ml 
In supplemented media to varying concentrations of con A. 
o, RPMI-1640 + 10% HIABS; D, RPMI-1640 + 5% HIABS;
A, RPMI-1640 +2.5 HIABS; •, N-T + 10% HIABS;
■, N-T + 5% HIABS; 4, N-T + 2.5% HIABS.
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200
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any of the con A values tested (Fig. 22).
For evaluation of the filter media performance, standard statis­
tical analyses were used. A two-way analysis of variance of all the 
log transformed raw data showed statistically significant differences 
in performance between the filter media (F - 34.66; VI ■ 3, V2 ■ 80). 
The internal data were very good (error mean square “ 0.0048). 
Multiple comparisons identified the GF/F medium as being statis­
tically inferior to each of the other three media at I * < 0.05
(Table 15). The GF/F medium compared favorably with the others in
collection of radioactivity in unstimulated cells, and somewhat 
less favorably with cells treated with con A at 5 yg/ml (Table 15) 
at higher doses of the mitogen, however, the GF/F filter medium 
clearly was unacceptable. There were no statistical differences in 
the performance of 934-AH, GF/A and GF/C media (Table 15), but the 
radioactivity recovered on GF/A and GF/C media always was equal to 
or greater than that recovered on 934-AH medium.
HLMF Dose Response. HLMF-active fractions from the Bio-Gel 
F-100 column in the molecular weight ranges of 30,000-50,000 and
12,000-20,000 were serially diluted and assayed for HLMF, and 
TCGF activity (Fig. 23). The 30,000-50,000 molecular weight peak 
demonstrated significant HLMF activity, which behaved in a dose 
dependent fashion. The pooled proteins of lower molecular weight 
had essentially no HLMF activity, although the individual fractions 
used to form the pool did have activity.
Ho TCGF activity was observed in either peak at any concen­
tration. Commercially prepared TCGF controls, however, demon­
strated significant activity, the magnitude of which was not
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Figure 22. The proliferative response of 2 x 10** PBL/ml to 
varying concentrations of con A in 107 HIABS (o)» and 107 
heat-inactivated serum autologous to donor cells (•).
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TABLE 15
95X Confidence Limits Comparison of Filter Meditf*
Con A (gg/ml) 934-AH GF/A GF/C GF/F
0 2,6251^ 2.7051 2.6489 2.7287
5 5.1498 5.1469 5.1441 5,0431
10 5,1364 5.1895 5.1969 4.9615
15 5,1094 5.1747 5.2001 4.8836
4.503^ 4.5541 4.5475 4.4042
df - 80 S2 - 0.0048 N ■ 6
Comparisons
934-AH vs GF/A 4.5033 - 4.5541 -0.0508 N.S.d
934-AH vs GF/C 4.5033 - 4.5475 -0.0442 N.S.
934-AH vs GF/F 4.5033 - 4.4042 0.0991 Sig.e
GF/A vs GF/C 4.5541 - 4.5475 0.0066 N.S.
GF/A vs GF/F 4.5541 - 4.4042 0.1499 Sig.
GF/C vs GF/F 4.5475 - 4.4042 0.1433 Sig.
952 confidence level ■ ± 0.0602
Characteristics of filter media is given In Table I; page 46.
± 0.0857 (for all means)
°± 0.0426 (for all average means)
^Not significant 
eSignifleant
ioi
Figure 23. Activation of PBL by serial dilutions of pooled 
active fractions obtained from Bio-Gel F-100 chromatography of 
30 X concentrated P supernatants. Points are expressed as X-fold 
concentrations of the original supernatant volume.
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diminished even at 1/8 dilutions of the original material.
Subpopulation Target Identification. Standard HLMF assays 
were performed using as targets unfractionated PBL, T-cell, and B- 
cell enriched populations obtained as previously described. Samples 
of HIMF active unfractionated supernatants, pooled 30,000 molecular 
weight active fractions from Sephadex G-100 column chromatography, 
and the pooled 30,000-50,000 active region from the Bio-Gel F-100 
column. Mitogenic indices of all samples were greater than 1.0 
when assayed against unfractionated PBL (Table 16). The Mis of 
the T-cell enriched population ranged from 1.53 to greater than 
9.48. The mitogenic Indices of the B-cell enriched population 
were generally less than for either the unfractionated or T-cell 
enriched population, but were positive in all but one case.
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TABLE 16
Proliferative Response of Human Lymphocytes 
to HLMF Active Supernatants
Human Mononuclear Cells
Stimulant Unfractionated T-cell B-cell
PBL enriched enriched
H l° MX MI
Whole Supernatant0
1 6.11 3.24 1.80
2 4.44 9.48 1.92
3 7.24 6.07 2.04
MF Active Fraction^
*1 3.30 2.38 1.31
F 2 4.06 2 .21 0.97
f3 3.68 5,80 2.58
MF Active Fraction^
F 1 1.05 1.99 2.06
F 2 1.82 1.53 2.54
infractions ted MF active supernatants 
Pooled 30,000 molecular weight active region from Sephadex G-100
°MI ■ c*)m test 
cpm control
^Pooled 30,000-50,000 molecular weight active region from Bio-Gel
P-100
CHAPTER 4 
DISCUSSION
It has been known for many years that the humoral and cellular 
Immune systems function synergistically In response to antigen 
stimulation. The mechanism of communication, and regulation of their 
response, however, has been poorly understood. More recently, It has 
been observed that certain soluble products of the activated cells 
have the capacity to regulate the behavior of populations of cells 
not directly Involved In the original stimulation. The responsible 
factors which function In a hormonal manner to regulate the magnitude 
and duration of an Integrated Immune response are termed lymphoklneB 
or monokines (2). In the last several years lymphoklnes have been 
partially characterized biologically and physiochemically. The 
Interleukins 1, 2, and 3 appear to have many common physiochemical 
features with regard to molecular size, charge heterogeneity and 
lability. They each, however, demonstrate quite specific functions 
in controlling cellular response to stimulation.
The major problem with obtaining definitive biological and 
physlochemical Information on all lymphoklnes is the inherent difficulty 
created by the small Initial amount of lymphokine material. This 
difficulty Is compounded by poorly defined handling and assay procedures 
which result in substantial losses before isolation and purification.
In many cases, the presence of serum proteins added to stabilize 
responding cells during activation significantly Interferes with the 
purification to homogeneity of an active, de novo product of the 
activated cells.
In Investigating the lymphokine, HLMF, it was necessary to examine
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the methods of procuring larger and more active supernatants by screen­
ing alternative sources of cells, defining the culture conditions for 
optimum yield and probing methods of handling which resulted In minimal 
losses. The biological assay was examined in the areas that could 
Increase sensitivity, thereby leaving greater quantities of the par­
tially pure factor for physiochemical characterization. The original 
source of HLMF was human PBL, but only limited quantities of cells are 
obtainable from single donors. Alternate cell sources are tonsils 
which are routinely removed as a result of recurrent tonsillitis.
Tonsils are lymphatic organs which contain essentially equivalent 
numbers of T and B lymphocytes (201, 202) and very low numbers of 
monocytes (202). The cells from tonsils have been reported to pro­
duce several lymphoklnes Including Interleukin 2 (87), colony stim­
ulating factor (203), and lymphotoxln (204). As a prerequisite to 
the use of tonsil cells as a source of HLMF, It was necessary to 
directly compare PBL and tonsil lymphocytes with respect to their 
Initial states of activation, response to the stimulating mitogen, and 
any modifying effects which might occur due to required addltiveB.
Because the tonsils are assaulted continually by microorganisms 
due to their location In the oral cavity, It Is necessary to reduce 
the possibility of microorganism growth during transportation to the 
laboratory and during processing and culturing of the tonsillar cells. 
This is accomplished In part by transporting the tonsils, and later 
culturing their cells in media fortified with various antibiotics. 
Mycologlcal organisms are frequently found In the oral cavity and the 
use of specific antimycotlc agents Is recommended to avoid fungal 
contamination. Amphotericin B (Am B) was used in these studies for
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this purpose, but It was necessary to specifically Investigate Its 
effect on peripheral blood and tonsillar lymphocyte activation because 
of the following literary citations regarding Its effects on various 
immune responses.
Amphotericin B (Am B) Is a polyene antibiotic used not only for 
treatment of systemic and deep-seated mycotic Infections, hut also to 
protect against mycotic contaminations in cell cultures during 
incubation and storage (205). Some investigators use Am B as a 
combination drug during cancer therapy (206, 207). There are reports 
of the drug causing immunopotentlatlon (208-210), augmentation and 
adjuvant effects (211, 212), mltogenicity (213) and suppression 
(214-216) with varying normal systems. The drug also causes various 
in  v itro  effects on cell lines (217-220). This brief literature review 
warranted an evaluation of the Am B effect on tonsillar and peripheral 
blood lymphocytes. Experiments were undertaken to determine the 
normal response of these cells to con A. This was followed by exper­
iments to detect any effect the presence of Am B might have on the 
normal cellular response to the mitogen.
It has been known for a long time that con A stimulates prolifer­
ation of lymphocytes. In my experiments, the shape of the dose re­
sponse curves indicated that the human PBL underwent a typical prolif­
erative response to con A. It also was noted that when the concentra­
tion of the PBL was increased while maintaining constant con A levels, 
the uptake of H-thymidlne decreased, and the radioactivity in PBL 
cultured at 4 x 10®/ml was less than half that In PBL cultured at 
1 x 10®/ml or 2 x 10®/ml. Previously, other investigators demonstrated 
that Increasing the concentration of con A while maintaining the cell
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concentration constant resulted In increased %-thymidine Incorporation 
(221, 222). My results suggested that the response of PBL to con A 
under the conditions described depended on several variables Including 
the extent of binding of con A by serum proteins, the ratio of number 
of cells to concentration of con A and the ability of the cells 
themselves to respond to a lectin. In general, however, the magni­
tude of the Incorporation of %-thymidine was directly dependent on 
the availability of con A on a per cell basis.
Although the responses of PBL to 10 pg con A/ml usually were 
enhanced If Am B was present at 2.5-5,0 vg/ml during culture, some 
cases of negligible effect or even suppression were noted at the 
Intermediate doses. When the concentration of the drug was raised 
to 10 pg/ml, however, the PBL responses to con A always were decreased 
significantly. Am B has been reported both to enhance and to suppress 
lymphocyte responses. Contact sensitivity of 2,4-dinitrofluorobenzene 
was augmented In mice by Am B (209), and the drug reversed a form of 
tolerance to 2,4-dinltrobenzene-l-sulfonate (223). Humoral Immunity 
In mice also was enhanced by Am B (212). As a result of their studies, 
however, Ferrante et al. (224) concluded that Am B suppressed the 
delayed type hypersensitivity response to sheep red blood cells in 
mice, and had no effect on the antibody response. The results are just 
the opposite of those reported by Blanke et al, (212) and by Shirley et 
al. (210). The time of administration of Am B to the mice as well as 
the dose of the drug may have been Influential on the results.
Ferrante et al. (224) reported that Inhibition occurred if Am B was 
administered after the day of priming or on the same day as challenge, 
but administration on the day of priming had no effect. On the other
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hand, Blanke et al. (224) noted enhancement of 2,4-dinitrofluoroben- 
zene responses when Am B was administered on the day of priming, and 
Shirley et al. (209) reported enhancement of the response when Am B 
was administered with priming and one day after priming.
In vivo sensitization of mice with 2,4-dinitrofluorobenzene plus 
Am B led to enhancement of the in vitro proliferative responses of 
spleen and lymph node cells to 2,4-dinltrobenzene-l-sulfonate. Aug­
mented proliferation of lymph node cells was found In the nylon-adher­
ent cell fraction which comprised T and B cells. It was concluded 
that the lmmunopotentlating effect of Am B may be the result of Its 
selective Interaction with a subset of T cells which results In 
Impairment of the normally Induced suppressor regulation that limits 
the magnitude and duration of Immune responses (210), Similarly, the 
enhanced responsiveness of human PBL to a mitogen, noted here, may 
reflect a depressing effect of Am B at intermediate concentrations 
on suppressor cells.
There have been several reports that Am B inhibited the activa­
tion of lymphocytes by con A, FHA, and certain antigens. DHA synthesis 
in human PBL cultured with PHA, con A, pokeweed mitogen (PHM), purified 
protein derivative (PPD) and In mixed lymphocyte culture was Inhibited 
progressively by Am B at levels of 2-10 ug/ml (215). That Am B was a 
potent inhibitor of activation of PBL by PHA and FWM also was 
reported by others (216). The response of mouse spleen lymphocytes 
to PHA or llpopolysaccharlde V was inhibited by Am B at 1, 5, or 25 
hg drug/ml (224). The data Indicated that Am B had a greater effect 
on the T-cell than on the B-cell response. The results reported here 
demonstrated that con A activation of PBL was strongly Inhibited by
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Am B at 10 tig/ml. At this concentration of the drug, the conclusion 
drawn substantiated those of others (215, 216, 224) who also reported 
inhibition.
Tonsil cells were active In the absence of deliberate in  v itro
stimulation. This preactivation phenomenon occurred repeatedly, and
it has been reported by others (225). It was assumed that it was the
result of in  vivo stimulation by microorganisms. Am B reduced the
3
spontaneous uptake of H-thymldlne by TL to PBL background levels 
at 5-10 pg Am B/ml. The data are consistent with the suggestion that 
Am B acts on T-blast cells (224).
The tonsil lymphocyte population responded well to con A even 
though some of the cells were preactivated. Tonsils comprised 30-552 
T cells and 38-602 B cells. This was considerably different from the 
distribution in peripheral blood which comprised 60-802 T cells and 
152 B cellB (201, 202). Although there was a difference In the 
percentage of T cells in tonsils and blood, the magnitude of the 
response of con A-stlmulated tonsil cells was as great as that of 
con A-stlmulated PBL at the same cell concentration. Unlike PBL, Am 
B markedly reduced the proliferative response of tonsil cells at all 
concentrations of the drug tested. The reduction In radioactivity 
was greater than could be accounted for by the diminished prolifer­
ation of preactivated cells alone caused by Am B. Further, the per­
centage reduction of proliferation of tonsil cells to con A In the 
presence of 10 pg Am B/ml was greater than the reduction seen In PBL 
at that level. It can be concluded that tonsil cells were much more 
sensitive to inhibition of proliferation by Am B than were PBL.
An apparent inhibition of the proliferative response could occur
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if the cells were killed by the drug. The attempts to determine cell 
viability after culture with Am B and con A suggested viability was 
good, but technical problems related to cell clumping made the 
experiments unsatisfactory. Moreover, Ferrante et al. (224) reported 
that Am B at 5 ug/ml was not toxic to mouse spleen cells after 48 hr 
culture (224).
Higher densities of tonsil cells responded better to con A in 
the presence of 5-10 ug Am B/ml than lower densities. For example, 
when the concentration of Am B was 5 ug/ml, the peak responses of cells 
at a density of 2 x 10®/ml or 4 x 106/ml were 2.5 and 3.4 times 
respectively greater than the response at a density of 10 /ml. When 
the concentration of Am B was raised to 10 ug/ml the 2 x 106/ml or 
4 xlO^/ml to 10^/ml ratios ranged from 34 to 79. This was primarily 
due to the greater effect of 10 ug Am B/ml on the lower cell densities, 
thereby creating significantly higher ratios by lowering the denomi­
nator function of the SI formula.
It was concluded that Am B at 2.5-5.0 ug/ml enhanced the response 
of PBL to con A, but at 10 ug/ml the drug suppressed the response.
All doses of Am B tested inhibited both spontaneous proliferation and 
con A-lnduced proliferation in TL, In spite of this inhibition, the 
TL population responded to various doses of con A in the presence of 
Am B.
After reviewing the available data for tonsillar lymphocytes, it 
was surmised that they were unsuitable for use as HLMF producer be­
cause of their pre-actlvated state, and the effect of Am B on the 
con A-stlmulated population. After electing to continue use of human 
PBL for HLMF production, experiments were undertaken to determine the
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conditions necessary for optimum factor production.
The density of lymphocytes responsible for the greatest amount 
of HLMF activity In supernatants when cultured In Neuman-Tytell 
serumless medium was 10 /ml. The addition of 2-mercaptoethanol to the 
culture resulted In Increased HLMF activity over that generated In its 
absence. Other investigators also noticed the beneficial effect 
of mercaptan on other lymphokine production (7 3 , 226, 227).
The failure to find HLMF activity in supernatants from cells 
cultured at the loweBt density probably was due to there being so 
very little produced that it was not sufficient to activate target 
cells. A similar situation occurred when less than 10® CBA thymo­
cytes/ml were cultured with con A. So little costlmulator, now 
referred to as 11-2 (73), was secreted that blastogenesls could not 
occur (67, 73).
When the stimulating doBe of con A was 5 or 10 Mg/ml, HLMF 
production peaked within 24 hr culture. It appeared that whatever 
cells were capable of producing HLMF when stimulated with these doses 
of con A did so within 24 hr but did not continue to produce 
lymphokine thereafter. At doses of 15-35 Mg con A/ml, HLMF production 
also occurred during the first 24 hr culture, and continued 
in the absence of replenished con A for the next 24 hr. It was 
passible, however, that in the latter cases, the increased incorpo­
ration of % - thymidine might have been partially attributable to the 
effects of 11-1 and 11-2. HLMF was produced by non-proliferating 
cells at all doses of con A. Proliferation in the producer-cell 
population began at the lowest dose of con A and gradually progressed 
with time toward the higher doses. During the time period that was
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studied, proliferation did not occur at the highest doses. Others 
have shown that there were optimal doses of the lectin to Induce 
proliferation, and when the dose became too great, suppression of 
proliferation occurred (96, 97).
11-1 Is produced by monocytes and It augments lectin-Induced 
lymphocyte proliferation (72, 228). This probably 1b an Indirect 
effect with proliferation really being the result of 11-2 whose 
production Is induced by the 11-1 (94, 119-122, 228). 11-2 is a T-
lymphocyte product which Induces proliferation of activated T 
lymphocytes (18-20). This lymphokine has no mitogenic effect on 
unstimulated lymphocytes (75, 76, 85, 229-231). The supernatants 
used In the experiments reported here contained con A, and it was 
necessary to inactivate the lectin to distinguish its activity from 
that of HLMF, and to prevent the development of mitogen-activated 
lymphocytes which might respond to 11-1 or 11-2 . o-mm completely 
Inhibited the action of con A when the Inhibitor concentration was 
0.1 M. This Inhibition resulted from a-mm occupanylng the glucose- 
binding site on the lectin. It was noted that spontaneous low level 
proliferation of FBL also was reduced. This probably was related to 
the high osmolarlty Imposed on the cells. At any rate, the mitogenic 
activity In the supernatant seemed to be Induced by a soluble mediator 
which probably was not 11-1 or 11-2 .
It was previously demonstrated that amphotericin B at 2,5 or 5 
pg/ml usually enhanced the proliferative response of PBL to con A, 
but when the drug was used at 10 pg/ml, the response of the FBL 
always was significantly below that of the cells treated with con A 
in the absence of amphotericin B.
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Experiments were undertaken to determine if HLMF production 
could be augmented in the same manner as the previously observed con 
A-lnduced PBL blastogenesis. The results were somewhat inconclusive 
in that expression of HIMF wbb reduced or unchanged in supernatants 
of cultures which received doses of Am B that previously had stimulated 
proliferation, and at higher doses that had inhibited proliferation. The 
data trends were consistent with a given set of experiments, however. If 
profileratlon of con A-treated PBL was due to 11-2, then amphotericin 
B as used in the previous work (232) must influence the production 
or the effect of that lymphoklne, depending on the dose of the drug. 
Since there was inhibition or no effect, but never a stimulation of 
the expression of HLMF, the data suggested that amphotericin B may 
affect HLMF differently from the way it affects 11-2.
The Induction of HLMF production by mitogens appears to be 
temporary. HLMF production usually dropped in cases where no 
additional con A was added after the first 24 hr incubation. When 
con A was added to the culture with fresh medium after 24 hr 
incubation, equivalent or greater amounts of HLMF were produced.
The mechanism which abrogates the HLMF production In the absence of 
subsequent con A addition is not known; however, the possibility of 
suppressor action against HLMF-produclng cells as suggested by 
Gullberg et al. (96, 97) is possible.
The biological action of soluble mediators occurs at very low 
concentrations on the order of M (228). To minimize losses
on limited amounts of partially purified factor it was necessary to 
determine the optimum procedures for handling and storage. Assay of
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Bamples Btored for short periods at -80° C showed only minimal activity. 
After prolonged freezing at -80° C, however, the activity usually was 
not reduced below that In untreated samples stored at -10° C, Perhaps 
some kind of suppressor was gradually destroyed while the sample was 
frozen. In contrast, Mier and Gallo (231) reported that partially puri­
fied TCGF was unstable at -70° C. When supernatant volumes In my experi­
ments were reduced by diaflltratlon using a YM-10 membrane and the retentates 
were frozen at-80° C, HLMF activities were poor after thawing. They 
were about the same as those demonstrated In supernatants which simply 
were stored at -80° C for a short time. The YM-10 membrane was 
selected because it was designed to bind less protein (233) than other 
dlafliter membranes. The conclusion, however, Is that the membrane 
bound the HLMF leading to a loss of activity. When samples were 
dlalyzed In NH^HCOg solution before lyophillzatlon, they were active 
when rehydrated. If the loss of activity following diaflltratlon was 
attributed to an Inhibitor being In the retentate, then it should also 
have been retained within the dialysis sack, making the HIMF inactive.
Although the mechanism of blastogenesis Induction by con A re­
quires the Intermediate action of Interleukin 2, the end result Is 
target cell proliferation, just as Is the case for HIMF. a-mm can be 
used to block the con A effect, but any purification scheme for HLMF 
eventually requires the removal of the mitogen. Several methods of 
HLMF-con A separation were examined, based on the literary documenta­
tion of the affinity interactions and molecular size of the mitogen.
As suggested by Northoff et al. (37) removal of con A from solutions 
or media In the absence of serum proteins could be accomplished without 
difficulty. The Inclusion of serum, as was required for HLMF produc-
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tlon In RPMI-1640, interferred with the con A removal such that 
Sephadex G-100 affinity chromatography was not acceptable. Other 
Investigators have reported similar difficulties with con A removal 
when serum was included In the medium prior to lymphoklne production.
In an attempt to avoid the necessity for serum, the N-T medium was 
employed, since unlike RPMI-1640, It requires no protein additives 
to support lymphocyte viability and growth.
Attempts to fractionate 30-fold concentrated HLKF-actlve super­
natants In N-T medium over Sephadex G-100 resulted in significant 
contamination of con A in the fractions eluting near the total column 
volume, even though HLMF activity eluted earlier in the 25,000-30,000 
d range. Fractionation of 30-fold concentrated N-T medium containing 
150 pg con A/ml led to similar elution profiles which suggested that 
an inhibitor of the con A-dextran Interaction was present in the N-T 
medium. Subsequent fractionation on Bio-Gel P-100 of the fraction 
taken from Sephadex G-100 which were contaminated with the low molecular 
weight con A suggested that the actual size of the apparently low 
molecular weight mitogen was greater than 35,000. This also supports 
the notion that the apparent low molecular weight of contaminating 
con A in the Sephadex G-100 fractionation experiments was artifactual. 
This artifact was probably due to an endogenous inhibitor in the N-T 
medium whose molecular weight corresponded to the position where con 
A was observed.
Commercially-obtained Afflgel-ovalbumin was used to attempt removal 
of con A from HLMF-active supernatants and experimental controls. Afflgel, 
which has covalently-bound ovalbumin as the affinity ligand, success­
fully removed contaminating con A from active supernatants, but was
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far too expensive for the large scale operation required to obtain 
the significant amounts of HLMF needed for subsequent physiochemical 
end biological characterization.
Literature sources site the molecular weight of con A to be
55.000 at pH values less than 6 , and greater than 100,000 d In pH 
ranges greater than 7.0 (165). Molecular sieve chromatography of 
con A on Bio-Gel P-100 repeatedly demonstrated its molecular weight 
under the given experimental conditions to be 45,000 d. When active 
concentrated supernatants were fractionated, the con A and HLMF 
activities were found to overlap significantly. However, when 
ovalbumin was added to HUlF-active supernatants at a concentration of 
33 tig/ml prior to concentration before fractionating the supernatants, 
the elution profile of con A was shifted significantly toward the 
exclusion volume. This presumably occurred because of binding of con 
A to ovalbumin, a glycoprotein. The absorbance of the eluted material 
suggested there was some unbound ovalbumin, because a maximum of 
light absorption was noted coincident to the elution position of the 
control (ovalbumin) sample, and was not observed In the previously 
described 30-fold concentrated supernatants which did not contain 
ovalbumin. This appears to be a promising method for rapid separation 
of residual con A from H W F  In concentrated supernatants.
In the ovalbumin-fractionated supernatants, there appeared to be 
greater recovery of active material In the 30,000-50,000 molecular 
weight range, but there was significant HLMF activity In the 12,000-
20.000 range, too. The bloactlvlty associated with the lower molecular 
weight entity did not appear in chromatographs done in the absence of 
ovalbumin. This presumably was attributable to stabilization by
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ovalbumin of smaller molecular weight forms of HLMF. Previously, 
the smaller sized HLMF may have been lost during handling prior to 
assay. Certainly, other lymphoklnes such as LAF, have been 
reported to bind to glassware In the absence of other proteins.
The observation of a 12,000-20,000 d and 30,000-50,000 d form 
suggests the possibility of self-association, although two distinct 
forms may occur. The notable absence of the lower molecular weight 
form In those supernatants fractionated In the absence of 
ovalbumin could suggest extreme lability of the smaller molecular 
weight activity In the absence of exogenous protein.
The largest molecular weight form eluted very close to the 
exclusion volume, but was so contaminated with con A that further 
characterization was not attempted. Although the possibility 
existed that the larger sized a-mm-resistant activity may actually 
represent a concentration of con A in excess of that which can be 
inhibited by 0. 1 u-mm, equally possible Is the association of 
HLMF with either de novo-produced lymphocyte proteins or the 
exogeneous ovalbumin. McDaniel (234) reported the association of 
another lymphokine, macrophage activation factor, with albumin and 
o2-macroglobulin when the factor was generated in a serum-free 
culture system.
Isoelectric focusing of the Afflgel-ovalbumln-treated HLMF- 
active supernatants resulted in two peaks of activity. The activity 
at pH 6-7 is certainly suspiciously close to the pi reported for 
11-2 (100). However, the Inability of 11-2 to directly activate 
target cells in the absence of other stimulation drastically reduces 
this possibility (75, 76). Lower pi's for other lymphoklnes have
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but not for HLMF.
Isoelectric focusing of the 50,000-70,000 d and 12,000-20,000 d 
active fractions from the Bio-Gel P-100 chromatography resulted in 
profiles decidedly different from one another. The lower molecular 
weight fraction contained three areas of activity, with the largest 
occurring In the pH range 3.4 to 4.6, but with significant activity 
at 5.2, 5.7, 8.7, and 9.5. The larger molecular weight chromato­
graphic fraction had greater activity at pH 3.25 and 5.11, but there 
was no other significant activity until the pH values exceeded 8.0. 
These data were in contrast to thoBe presented by Hood et al. (60).
They recovered a B cell-LMF which had a molecular weight of 20,000-
50,000 d when sieved through Sephadex G-100. The fractions with mo­
lecular weights less than 26,000 d focused isoelectrically between 
pH 4.5-7.5 and chose whose weights were greater than 26,000 d had a 
pi of 7,6-8.4.
Aside from the possibility of multiple factors being represented 
by the different peaks,' the breadth of the activity suggested signifi­
cant charge heterogeneity, not unlike that reported for other 
lymphoklnes (74, 101). There are reports of post-translational 
glycosylation among lymphoklnes (101) and charge heterogeneity could 
certainly result from such Intracellular modifications.
My experiments demonstrated that HLMF retained biological activity 
after exposure to pH values from 2-7. Similar experiments by others 
demonstrated some lymphoklnes remain active after exposure to pH values 
ranging from 2-10 (98). Although this Information was of extreme 
value in designing handling procedures, it did not discriminate between 
HU1F, and other lymphoproliferative factors such as the Interleukins.
119
In thermal stability experiments, HLMF activity was only partially 
destroyed by exposure to 56° C for 30 mln. Higher temperature for 
shorter periods destroyed essentially all the activity but without 
obvious visible denaturation. This was in agreement with the reports 
of Sundar et al. (49) who reported complete loss of activity after 
treatment at 100° C for 10 min, and with Rutenberg et al. (47) who 
reported inactivation after exposure at 70° C for 5 mln. It contra­
dicted, however, others who reported HLMF activity after exposure to 
56° C for 30 min (13, 14, 59).
HLMF proved to be resistant to trypsin digestion. This did not 
suggest however, that HLMF was or was not protein in nature. Others 
have reported loss of HLMF activity after trypsin exposure, but 
found HIMF to be resistant to treatment with RNase, neuraminidase, 
and a-amylase (13, 14, 59). 11-2, however, was found to be sensitive
to trypsin under similar conditions (98, 100), This provides another 
distinguishing piece of evidence between the interleukins and HLMF.
Assay of HLMF generally requires significant amounts of the 
partially purified material. It was decided that if biological assay 
parameters could be modified to increase sensitivity, then smaller 
quantities of material could be used for assay leaving more partially 
purified HLMF for subsequent physiochemlcal analyses or purification 
steps.
In experiments measuring the effect of cell density on biastogenic 
activation, the greatest density of lymphocytes incorporated signifl-
a 6
cantly less JH-thymidine than lower densities (1 or 2 x 10 cell/ml).
Of the lower cell concentrations, 1 x 10® cells/ml usually incorpo­
rated slightly more radioactive material, but the 2 x 10® cell/ml was
120
not significantly less. A density of 2 x 10** cell/ml was selected for 
use based on the consideration that should HLMF only activate a limited 
subpopulation of cells, It would provide greater numbers of reacting 
cells than the lowest density tested.
Further experimentation using 2 x 10** cells/ml suspended In RFMI- 
1640 and N-T, and three different concentrations of HIABS were under­
taken to determine the best conditions for assay. In every case N-T 
medium supported blastogenesis significantly better than RPMI-1640,
When HIABS was added to N-T medium to 2.52 (v/v) , ^ H-thymidine Incorporation 
by the cells was at its best. In contrast, a serum concentration of 
10% appeared to be optimum level when assaying for HLMF, These con­
clusions were founded on Information obtained from the con A dose 
response experiments. In those experiments, con A concentrations 
resulting in maximum blastogenesis were higher In the presence of 10% 
serum than In the presence of lower serum concentrations. This was 
probably a consequence of the binding of con A to serum glycoproteins 
which may have reduced the con A available to activate cells. For con 
A-containlng HLMF-active supernatant assays, those conditions which 
offered maximum blastogenesis and with maximum protection of cells from 
con A were considered optimum. Since no significant differences were 
noted between HIABS and autologous serum, the former was chosen be­
cause It offered Internal consistency among reagents.
The cells used In bloaBsays are most frequently harvested using 
multiple automated sample harvesters (MASH). These units offer rapid 
collection of microsupematants, and with simultaneous deposition of 
cells on a filter media. Since viable cells which were activated in 
an assay have assimilated the radiolabel, It Is Important to select the
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filter medium which offers the highest retention of these cells. The 
automated harvester (MASH II) was utilized extensively in this labo­
ratory. An unexpected and serious deterioration in recovery on 934-AH 
filter medium of expected radioactivity from human lymphocytes 
stimulated with con A or with HLMF-rich supernatants occurred. A 
considerable amount of time and effort was expended trying to Identify 
and correct the situation. Several small problems were associated 
with the MASH unit, the most serious of which were tiny leaks in the 
pooling chamber. These problems were easily rectified. The major 
problem and the most difficult one to identify, however, had to do 
with the 934-AH filter medium. Eventually, it was learned that the 
medium had been manufactured outside of control limits. The data re­
ported here evolved from extensive efforts to correct the problem 
and to determine if that grade of filter medium actually was the most 
suitable for the work.
The characteristics of the filter media manufactured by Whatman 
Inc. which were tested are given in Table 1 . They were made of boro- 
slllcate glass microfibers without a binder. The wet strengths of the 
GF media were low but suitable for low suction filtration (235). The 
934-AH medium had a wet strength greater than 150 gm/lnch width (236). 
All of the media tested had high loading capacity. The data show 
that GF/F filter medium was unsuitable for use in the MASH II. Aspira­
tion of the cultures and washes was difficult. This grade filter medium 
was the thickest and was a finer particle retention than the others.
Although there were no significant differences in the performance 
of 934-AH, GF/A, and GF/C media, the radioactivity collected on the 
latter two was usually greater than that collected on 934-AH. In
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lymphocyte stimulation assays, the filter medium which is most effi­
cient in collecting the radioactivity Incorporated into DNA should he 
used. Often Investigators must deal with relatively low incorporation 
which manifests itself as only a few thousand counts per minute. GF/A 
or GF/C media are better choices than 934-AH medium. The coBt of the 
GF/C medium, however, is considerably greater than that of GF/A. This 
is probably a more Important factor than differences in performance 
in selecting GF/A or GF/C filters for investigations of lymphocyte 
transformation when using a multiple automated sample harvester.
Dose response assays were performed on the 12,000-20,000 d and 
30,000-50,000 d pooled active fractions, resulting from the Bio-Gel 
P-100 chromatography. The larger molecular weight material demon­
strated significant HLMF activity which behaved in a dose dependent 
fashion. The lower molecular weight material, however, essentially 
had no HLMF activity, even though the composing individual fractions 
had contained varying, but significant amounts of a-mm-reslstant 
activity. The lower molecular weight forms had only appeared during 
chromatography of active supernatants which contained exogeneous oval­
bumin. Subsequent loss of the activity from individually active 
fractions which were pooled following molecular sieving certainly 
tended to support the notion that extreme lability or glassware 
tenacity are characteristics of the lower molecular weight forms in 
the absence of exogeneous and presumably stabilizing proteins.
The absence of TCGF from either fraction w s b  unexpected. Although 
11-2 has a defined molecular weight of 15,000, Duncan et al.. (55) 
demonstrated minimal TCGF activity in the pooled 27,000-35,000 d HLMF- 
actlve material. This TCGF activity could be adsorbed by TCGF-dependent
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cytotoxic T-cell transformed lines. In thoBe experiments, however, 
no exogeneous protein was added to the HLMF-actlve materials which 
had been generated In N-T medium, and neither HLMF or TCGF activity 
was observed In the lower molecular weight areas. This also may 
reflect the Instability or adherence qualities of HIHF and TCGF In 
that system as well.
Target cell subpopulation studies failed to clearly demonstrate 
complete containment of the HIHF-responding cells in either the T- 
cell-enriched or B-cell-enriched subpopulation. The methods of 
subpopulation enrichment used in these experiments were well estab­
lished, and controls demonstrated adequate separation of E-rosette 
positive and negative cells Into the appropriate subpopulations. 
Reinherz et al. (17) separated cells based on their surface markers 
using a fluorescent activated cell sorter. That group demonstrated 
significant activation of all three subpopulations obtained (T-cells, 
B-cells, and Null cells), with the null cell population responding to 
a much greater extent than either T-cells or B-cells, Since the 
methods employed In this research would allow for Null cell conta­
mination of both T-cell-enrlched and B-cell-enrlched subpopulations, 
the data could be used to Indirectly support the report of Reinherz 
et al. (17) of Null cell activation by HLMF. Alternatively, Duncan 
et al. (55) procured B-cell enriched populations using similar T-cell 
depleting Isolation techniques and noted a selective B-cell-enrlched 
population activation by the Bio-Gel P-100 HLMF active fractions.
That group, however, also used T-cells for target cells even after 
cold hypotonic saline exposure. The hypotonic saline treatment was 
used to lyse remaining SRBC after Ficol-Paque density separation.
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The use of T-cells procured In this manner was deemed unacceptable at this 
time, since the possibility remained that the lysis treatment may have 
impaired the T-enriched populations HLMF response capability,
With regard to activation of both major subpopulations the 
distinct possibility also exists that multiple factors remain, as yet, 
unseparated even in the pooled column fractions, and indeed reactive 
cells of T-cell or B-cell specificity may be responding to distinct 
activating entitles. It also cannot be ruled out at this time whether 
HLMF as a single entity may possess the capability of activating cells 
of several population specificities.
A number of alternate but less widely used PBL fractionation 
procedures remain viable and should be tried. Until such time bb the 
specific subpopulation of HLMF responder cells can be identified via
fluorescent antibodies or radio- or fluorescent-labeled homogeneous
*
HLMF preparations, the biological separation procedures should be 
surveyed.
As a matter of convenience to the reader, a composite of the 
reviewed literature is provided in Table 17. References for particular 
quotations are keyed to the bibliography. Lastly, HLMF data presented 
in the dissertation have been collated into the table for ease of 
comparison.
In summary, the initial objectives were achieved in so much as 
it was demonstrated that HLMF productivity was dramatically increased, 
and handling and isolation procedures which allowed significantly 
higher yields of partially purified material were defined. The new 
assay procedures allowed detection of HLMF at lower concentrations of 
the partially purified material. Isolation and partial characterize-
TABLE 17
Literature and Experimental Result Comparisons
pH Proteins/
Cell Molecular Thermo Isoelectric
Factor Synonyms Source Weight Sensitivity Point Target Cell
11-1 LAF (112) Macro­ 11,000 (113) 7.0 (140) 11-2 producing
Mitogenic Protein 
(114)
Helper Peak (115)
T-cell-replacing 
factor III (116)
phage
(126-
131)
on
SDS—PAGE
12,000-15,000 (139) 
on
5.2, 6.0, 
6.9 (74)
T-lymphocytes
(119-122)
T-cell-replacing 
factor M4 (61)
B-cell-actlvating 
factor (117)
Ultrafiltration
1 2 .0 00-22,000 and
50.000-70,000
•
B-cell differen­
tiation factor 
(118)
on
Bio-Gel P-100 (141)
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TABLE 17 (cont)
Literature and Experimental Result Comparisons
Factor Synonyms
Cell
Source
Molecular
Weight
pH Proteins/ 
Thermo 
Sensitivity
Isoelectric
Point Target Cell
11-2 Thymocyte mitogenic 
factor (68)
T-lym- 15,000 ACA 54 Stable pH 2.7- 6.5 (98) Cytotoxic and
Co-stimulator (73)
photytes and 10.0 (98) 6 .8 , 8.0 helper T
Killer cell helper
(8 8 , 89 Sephadex (98) Stable 70° C (100) cells (85,
factor (68)
Secondary
cytotoxic T-cell
Inducing factor 
(69)
90, 91) 27,000-35,000 (55) 
on
Bio-Gel P-100
x 15 min (98) 
trypsin, 
chymotrypsin 
(10 0) and 
subtllisin 
sensitive (98)
103, 107, 
108)
to
o\
TABLE 17 (cont)
Literature and Experimental Result Comparisons
pH Proteins/
Cell Molecular Thermo Isoelectric
Factor Synonyms . Source Weight Sensitivity Point Target Cell
HLMF
(Litera­
ture)
Mitogenic 
factor (55)
MF (17)
T-cells
(13-22)
15,000-31,000
on
(11-14)
Stable 56° C 
(13, 14, 59) 
Sensitive 70°
8 .0-8 .5 
(50)
C 7.6-8 .4
T cells 
(13, 14, 17, 
19)
Sephadex G-100 x 5 min (47) (60) B-cells
29,000-56,000 (11) Sensitive 4.5-7.5 (11, 13, 14,
and 100° C (60) 17, 19, 55)
post-albumln x 10 min (49) Null cells
on (17)
Sephadex G-200 (47)
40.000-45,000 (30) 
and
27.000-35,000 (55) 
on
Bio-Gel F-100
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TABLE 17 (cont)
Literature and Experimental Result Comparisons
Factor Synonyms
Cell
Source
Molecular
Weight
pH Proteins/
Thermo Isoelectric 
Sensitivity Point Target Cell
HLMF T-cells 1 2 ,00 0-20,000 Stable 2.0-7.0 A.2, 6.7
(Exper­ on Stable-Trypsin
imental) Bio-Gel F-100 Partial Loss
30,000-50,000 56° C x 30 mln
on Sensitive
Bio-Gel P-100 70° C x 10 mln
18,000-25,000 100° C x 5 mln
on
Sephadex G-100
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tion of the factor was significantly accelerated because a seruraless 
culture medium was employed, and this reduced the number of contami­
nating proteins. The ultimate goal of purification to homogeneity 
was not achieved, since even the Increase In yield of partially 
purified material would not preclude the eventual need for amounts 
of supernatant far in excess of that obtainable through single donor 
phlebotomies. Although HLMF was clearly shown to possess in  v itro  
characteristics decidedly different from the other lymphoproliferatlve 
factors, an unequivocal immunoregulatory function in  vivo was not 
defined.
The immediate direction of this research certainly should have 
several facets. Initially, the relative purity of the 30,000-50,000 
d active fraction from Bio-Gel P-100 column chromatography should be 
determined. This can be determined by the use of analytical 
isoelectric focusing or polyacrylamide gel electrophoresis followed 
by silver stain. This should be followed by development of monoclonal 
or natural antibodies to HLMF. This would facilitate not only the 
use of radioimmunoassay for quantitating HLMF, but also would allow 
selective immunoafflnlty chromatography techniques to be developed.
The latter have proven Invaluable in procuring quantities sufficient 
for purification to homogeneity of other lymphoklnes. Alternatively, 
discovery of an established transformed cell line which endogeneously 
or induclbly produces HLMF would allow significantly greater availabil­
ity of starting material for purification through current physlochem- 
ical technology. Identification of the specific HLMF-reactive cell 
population would allow definition of any in  vivo immunoregulatory 
function which the factor may possess. Eventual purification
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of the HDlF-receptar protein would provide the avenue for Investiga­
tion Into potential points of selective clinical Intervention for 
correction of HLMF producer-responder anomalies.
Information derived from the above mentioned experimental 
pathways will eld ultimately In defining the apparently complicated 
mechanism of lmmunoregulation. Understanding the products and 
activities of activated lymphocytes Is critical If Immunologists 
and clinicians are to use these regulatory molecules to selectively 
intervene In altering, amplifying or suppressing specific components 
of the Immune responses (153).
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